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Abstract 
Background. 
Roux–en-Y gastric bypass (RYGB) is the most successful treatment for obesity that 
results in sustained, long-term weight loss and improved insulin sensitivity. Generally, 
these benefits are mediated by gut peptides such as glucagon-like peptide-1 (GLP-1). 
However, their role(s) in some scenarios is yet to be investigated, for example in some 
patients who, following weight-reducing surgery, develop chronic intolerable nausea 
and vomiting (N&V) symptoms, in those undergoing a primary obesity surgery 
endoluminal (POSE) procedure, a new less invasive, incisionless weight-loss technique 
that seems to be effective for losing weight, or in ethnicities that have a high prevalence 
of obesity. 
Therefore, the aim(s) were to investigate systemic GLP-1 concentrations in three 
separate groups: 1) patients with prolonged N&V after metabolic surgery (Study I), 2) 
patients who had POSE for weight loss, compared to RYGB (Study II), and 3) an obesity-
prone, Arab population (Study III). 
Methods. 
Study I: female non-diabetic subjects were studied in five groups. Group 1: patients with 
N&V after RYGB surgery. Group 2: patients with no symptoms after RYGB surgery. 
Group 3: morbidly obese patients. Group 4: obese/overweight subjects. Group 5: lean 
healthy subjects. 
Study II: female subjects were studied before surgery (POSE and RYGB), and 1 week, 2 
months and 6 months after surgery, in the fasting and postprandial states. 
Study III: Arab non-diabetic female subjects were studied before and after a 388.6-kcal 
liquid mixed-meal challenge. 
Blood was collected in the fasting and postprandial states after a defined meal challenge 
(182.7-kcal meal used in Study I and 388.6-kcal meal used in Studies II and III). Systemic 
concentrations of glucose, lipids, insulin, GLP-1 and adipokines were determined using 
a routine chemistry analyser (Roche) or commercial ELISA. 
Subcutaneous (SC) adipose tissue organ cultures were incubated with recombinant 
GLP-1, and leptin concentrations were detected from the conditioned medium. 
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Results. 
Study (I): subjects with N&V post-RYGB had significantly elevated fasting GLP-1 levels 
compared to those without N&V (p = 0.035) and compared to morbidly obese, 
obese/overweight and lean subjects. Weight loss and glucose, insulin and GLP-1 
response to a 180-kcal meal challenge were similar in subjects with and without N&V. 
Fasting plasma leptin was significantly lower in subjects with N&V compared to those 
without N&V (p = 0.04). In vitro, leptin secretion was inhibited by GLP-1. 
Study (II): both POSE and RYGB patients lost a significant amount of weight early after 
surgery, with a concomitant decrease in leptin. However, only RYGB patients continued 
to lose weight at 6 months. Adiponectin increased at 2 and 6 months, and serum lipid 
levels were unchanged. First-phase responses (30 minutes) of insulin and GLP-1 were 
dramatically increased 1 week after RYGB only. 
Study (III): in the non-diabetic Arab subjects, the mixed meal provoked a similar GLP-1 
response to that reported in Caucasians. However, even in this apparently healthy 
population, postprandial hyperinsulinemia was evident. 
Conclusions. 
Subjects with persistent N&V post-RYGB surgery had elevated fasting GLP-1 levels 
related to their symptoms. Inhibiting GLP-1 with antagonists might help to ameliorate 
these symptoms. However, potential detrimental effects on weight maintenance and 
insulin sensitivity need to be considered. GLP-1 directly inhibits leptin secretion, so a 
decreased leptin level early after RYGB might be explained by an elevated GLP-1 level, 
and this could at least partially be explained by the alteration in GLP-1. 
POSE provides reasonable short-term weight loss without having an effect on GLP-1 in 
the morbidly obese but it is not as effective as RYGB. 
Finally, no significant lesion in systemic GLP-1 levels was seen in a cohort that could 
explain the obesity phenomenon in this population. 
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1.1 Definition of obesity 
Obesity is defined as an abnormal and inappropriate accumulation of adipose 
tissue that has pathological consequences such as insulin resistance and diabetes 
mellitus, cardiovascular diseases, sleep apnoea, osteoarthritis, cancer and 
depression [1, 2]. Body mass index (BMI), calculated as [weight (kg)/height (m)2], 
is used to classify weight as shown in Table 1.1 [3]. 
 
1.2 Prevalence of obesity 
Obesity is a global health issue with high prevalence that has proven particularly 
difficult to tackle. Although the effect of obesity on quality of life was observed as 
early as in the eighteenth century, its definition as a cause of ill health was only 
recorded in the nineteenth century. Obesity-associated morbidity and mortality 
rates started to be documented only at the beginning of the twentieth century [4]. 
In fact, the rapid increase in the incidence of obesity in the last six decades has led 
the World Health Organization (WHO) to consider obesity as a global health 
problem of epidemic proportions [5]. In 2010, it was reported that overweight 
and obesity might result in 3.4 million deaths and 4% of disability-adjusted life-
years around the world [6]. 
Globally, between 1980 and 2013, the number of overweight and obese adults 
increased from 857 million to 2.1 billion, and the prevalence of overweight and 
obesity increased by 27.5%. The proportion of overweight men grew from 28.8% 
to 36.9%, and the proportion of overweight women grew from 29.8% to 38.0% 
[7]. 
 19 
Classification BMI (kg/m2) 
 Principal cut-off points Additional cut-off points 
Underweight < 18.50 < 18.50 
     Severe thinness < 16.00 < 16.00 
     Moderate thinness 16.00–16.99 16.00–16.99 
     Mild thinness 17.00–18.49 17.00–18.49 
Normal range 18.50–24.99 
18.50–22.99 
23.00–24.99 
Overweight ≥ 25.00 ≥ 25.00 
     Pre-obese 25.00–29.99 
25.00–27.49 
27.50–29.99 
Obese ≥ 30.00 ≥ 30.00 
     Obese class I 30.00–34.99 
30.00–32.49 
32.50–34.99 
     Obese class II 35.00–39.99 
35.00–37.49 
37.50–39.99 
     Obese class III ≥ 40.00 ≥ 40.00 
 
Table 1.1 Classification of BMI according to WHO [2] 
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Figure 1.1 shows the worldwide prevalence of overweight and obesity, and 
obesity alone, among adults in developing and developed countries between 1980 
and 2013. In developed countries, men were more overweight and obese than 
women, while in developing countries, women were more overweight and obese 
[7]. 
In the United States, the incidence of obesity almost doubled within 10 years, 
between 1980 and 1990. It was suggested that if this increase in obesity rate was 
not controlled it would result in a decline in life expectancy [8]. Between 2011 and 
2012, over one-third of adults were obese. Overall, the obesity rate was greater in 
middle-aged (aged 40–59) than younger (aged 20–39) or older adults (aged 60 
and above). Moreover, the incidence of obesity was high in non-Hispanic black 
(47.8%) and Hispanic (42.5%) adults. The incidence of obesity in non-Hispanic 
Asians (10.8%) was lower than that in non-Hispanic whites (32.6%) [9]. 
In England, between 1993 and 2012, the percentage of normal-weight adults 
declined from 41.0% to 32.1% among men, and from 49.5% to 40.6% among 
women. For both sexes, the overweight percentages were stable (40% for men 
and 30% for women). The percentages of obesity increased from 13.2% to 24.4% 
among men, and from 16.4% to 25.1% among women [10]. 
In Arab countries, over the last three decades, obesity rates have increased in 
Egypt, Saudi Arabia, Oman and Bahrain among women, and in Bahrain, Kuwait 
and Saudi Arabia among men [7]. The Arab Gulf countries, in particular Kuwait, 
Bahrain, Saudi Arabia and United Arab Emirates, have the highest rates of obesity 
worldwide. The prevalence of obesity in Arab Gulf countries for the last 25 years 
has been higher among women, whereas the prevalence of overweight for the 
same period was higher among men [11]. In 2010, the percentages for obesity in 
females in those countries were as follows: Kuwait 55.2%, Qatar 31.6%, Saudi 
Arabia 36.4%, Bahrain 37.9% and United Arab Emirates 42% [12]. 
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Figure 1.1 Prevalence of overweight and obesity and obesity alone 
The prevalence of overweight and obesity (A) and obesity alone (B) among males 
and females increased between 1980 and 2013 in both developed and developing 
countries. However, it was lower in developing countries than in developed 
countries. Also, it was higher among men in developed countries, whereas it was 
higher among women in developing countries. 
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1.3 Obesity and insulin resistance 
Insulin resistance is a prediabetic condition that is associated with obesity. Some 
studies have suggested that insulin resistance might result from obesity [13]. 
Failure of adipocyte differentiation in response to high caloric intake and visceral 
adipocyte hypertrophy may contribute to insulin resistance. It is possible that 
secretion of inflammatory cytokines and adipokines from adipocytes causes 
insulin resistance in liver and muscle tissues. Another possibility is abnormal 
release of free fatty acids (FFA) from adipocytes and accumulation of ectopic 
lipids in liver and muscle tissue causing impaired insulin sensitivity in these 
tissues [14]. However, some obese individuals have no associated metabolic 
disturbance, have normal insulin sensitivity and are classified as metabolically 
healthy obese as opposed to pathologically obese [15]. It seems that 
environmental, behavioural and genetic factors also play a role in mediating 
healthy or pathological fat accumulation [15]. 
 
1.4 Mechanism of satiety 
There are two major issues when considering satiety. The first concerns the 
mechanisms that are attributed to meal termination, whereas the second 
concerns the mechanisms that govern intervals between meals. These 
mechanisms involve neural and humoral signals that interact with each other to 
a degree [16, 17]. 
Once food is ingested, satiety-inducing signals that reach the brain are initiated by 
mechanical or chemical stimulation of the gastrointestinal system, neural input 
related to energy metabolism in the liver, and gut peptide signals such as 
cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) [18-
21]. CCK is the most studied gastrointestinal hormone that transmits satiety-
related information to the brain. Gibbs and colleagues were the first group to 
report that administering purified or synthetic CCK to animals before a meal 
decreases nutrient intake in a dose-dependent manner [22]. This hormone is 
released from endocrine I cells of the duodenum and the jejunum during meal 
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consumption and acts on its receptors present on sensory fibres of the vagus 
nerve near the site where food passes from the stomach into the intestine [23]. 
Once these receptors are stimulated, they send a satiety signal through the vagus 
nerve afferent fibres to the brain to terminate meal ingestion [24]. Satiety 
information from the gut converges in the nucleus of the tractus solitarius (NTS) 
in the brainstem [25]. 
Furthermore, neuropeptide Y/agouti-related protein (NPY/AGRP) and pro-
opiomelanocortin/cocaine- and amphetamine-regulated transcript 
(POMC/CART) neurons in the arcuate nucleus are also involved in the satiety 
process [26, 27]. Leptin and insulin activate the POMC/CART anorexic effects and 
inhibit (NPY/AGRP) orexigenic effects, which reduces food intake [28-31]. In 
addition, these neurons project from the arcuate nucleus to other sites in the 
hypothalamus such as the paraventricular nucleus (PVN) and lateral 
hypothalamic area (LHA), that are also known to control food intake [31-33]. 
 
1.5 Gastric emptying 
Gastric emptying depends on complex coordination between the major motor 
patterns of the stomach. Once food is ingested, an initial gastric relaxation occurs, 
and the proximal stomach pushes the gastric contents forward by a process of 
tonic contraction, providing a driving force for gastric emptying. At the same time, 
peristaltic contractions originating from the mid-corpus progress in the direction 
of the antrum, cause grinding and sieving of solid food. This repetitive process 
leads to breakdown of food particles, mixes them with juices and forms a second 
drive that propels the food content distally. Opening and closing of the pyloric 
sphincter is the third mechanical factor in the control of gastric emptying. The 
pyloric sphincter closes the stomach during the terminal phase of a peristaltic 
contraction wave, preventing any content in the antrum from entering into the 
duodenum during mixing and grinding [34]. 
The influence of each of these three mechanical factors depends on the 
consistency of the food. In the case of liquid, gastric emptying is controlled mainly 
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by the pressure elicited by the proximal stomach and the opening of the pylorus. 
Gastric emptying in the case of solid food is controlled mainly by the peristaltic 
pump of the antrum [35]. 
The emptying rate of a meal is negatively correlated to its caloric content [36]. 
Other factors that affect gastric emptying rate are the acidity, osmolarity and 
viscosity of the meal [37, 38]. Once nutrients enter the duodenum, they activate 
the vagovagal reflex mechanisms and hormonal signals (e.g. GLP-1, PYY and CCK) 
which modulate gastric emptying [39-41]. Physiological or artificially induced 
inhibition of gastric emptying seems to be linked with increased feelings of satiety 
and fullness and termination of food intake [42-44]. Moreover, it has been found 
that a subset of patients with anorexia nervosa have markedly delayed gastric 
emptying, whereas some studies have suggested that obese people have rapid 
gastric emptying [45-47]. 
 
1.6 Hormonal control of food intake 
Most human subjects maintain a stable body weight over a number of years. To 
keep the weight stable, there must be mechanisms that regulate the energy 
balance, adjusting energy intake and expenditure [48]. These mechanisms involve 
the gut–brain axis (gut hormones and gut neuronal signals) and adipose–brain 
axis (adipokines) (Figure 1.2) [49]. Thus, there must be coordination between the 
brain, gut and adipose tissue. Disturbance in this coordination can impair the 
regulation of energy homeostasis and result in weight gain and obesity [50]. 
 
1.6.1 Adipose–brain axis 
Adipose tissue secretes a number of adipokines that provide the brain with 
information about long-term energy storage. These adipokines may enable the 
central regulation of energy homeostasis and help in the maintenance of body 
weight. The best-investigated adipokine that is involved in this action is leptin 
[51]. 
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Leptin was cloned and sequenced in 1994 by Freidman’s group [52]. It is 
produced in proportion to adipocyte mass, with serum leptin levels increasing as 
the percentage of body fat rises [53]. Other human organs such as the stomach, 
mammary tissue, placenta and heart also produce small amounts of leptin [48, 54, 
55]. Leptin plays a major role in regulating energy homeostasis and is considered 
a long-term mediator of energy balance. This hormone is capable of crossing the 
blood–brain barrier (BBB), and high concentrations have been reported in 
cerebrospinal fluid (CSF). Leptin suppresses appetite and increases energy 
expenditure to maintain normal body fat mass [56-60]. 
It acts on the brain by binding to leptin receptors (LEPR-B) to inform on the status 
of energy stores. In the brain, it acts through its receptors in the hypothalamus, 
and in particular in two neuronal systems. The first system is POMC and CART, 
causing suppression of appetite and increase energy expenditure. The second 
system is AGRP and NPY, causing an increase in appetite and food intake, and 
which is suppressed by leptin [61, 62]. 
The first evidence for leptin as a major mediator of energy balance was provided 
by Montague et al. They examined severely obese children with a congenital leptin 
deficiency as a result of a homozygous frameshift mutation in the OB gene. The 
children were normal weight at birth and rapidly developed severe obesity 
accompanied by overeating and increased appetite [63]. In another study, by 
Farooqi et al., subjects with a partial genetic deficiency in leptin had a higher 
prevalence of obesity, and were found to have a lower serum leptin level than 
control subjects. In these cohorts, leptin treatment led to an improvement in 
satiety, reduction in appetite, decreased adiposity, and increased weight loss [60, 
64]. 
Many obese individuals have high circulating leptin levels, and it is not known 
whether this increase in leptin is a cause or a consequence [65]. In addition, it has 
een shown that leptin treatment of most obese humans and animals is ineffective 
in reducing food intake and losing weight, so it has been suggested that an 
increased level of leptin in obese individuals is associated with leptin resistance 
[66, 67]. 
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Leptin resistance is most likely preceded by a long period of hyperphagia caused 
by a disruption in the leptin system [68, 69]. Hyperphagia causes elevation in 
circulating leptin levels, and as a result, the hypothalamus is exposed to high 
leptin levels that may attenuate the action of leptin on its receptors in the 
hypothalamus, leading to insensitivity of the hypothalamus to leptin, and 
continuous elevation in systemic leptin levels [48]. It has been reported that leptin 
resistance in the hypothalamus appears after chronic central leptin infusion in 
rats [70], and it has been shown that overeating causes leptin resistance in human 
subjects [68]. 
Leptin binds to its receptor (LEPR-B) in the brain and activates the Janus kinase–
signal transducer and activator of transcription (Jak-STAT) pathway, which is the 
main leptin signal transduction pathway. The binding process of leptin to the 
extracellular part of its receptor causes structural changes in the receptor that 
activate its related Jak-2 tyrosine kinase [71], and as a result induces 
phosphorylation of three intracellular tyrosine residues in LEPR-B. 
Phosphorylated Tyr985p stimulates SHP2 which involves ERK activation, and 
SOCS3 suppresses LEPR-B signalling as an inhibitory feedback. Phosphorylated 
Tyr1077 stimulates STAT5, and phosphorylated Tyr1138 stimulates STAT3 that 
facilitates the transcription of SOCS3 and causes its accumulation (Figure 1.3) [72-
74]. 
It has been suggested that overproduction of SOCS3 and protein tyrosine 
phosphatase 1B (PTP1B), which are the negative regulators of leptin signalling, 
might attenuate LEPR-B activity and therefore contribute to leptin resistance [65]. 
Destruction of central nervous system (CNS) SOCS3 or LEPR-B Tyr985 reduces 
food intake and weight in mice [75-77]. Similarly, dysfunction of PTP1B in the 
brain of mice stimulates leptin signalling and reduces adiposity [78, 79]. 
In addition, other pathways might also induce the attenuation of leptin signalling. 
Endoplasmic reticulum (ER) stress and the state of chronic low-grade 
inflammation that are related to insulin resistance are promoted in peripheral 
tissues (e.g. adipose tissue, liver and muscle), and may also be involved in the 
limitation of CNS LEPR-B signalling in obesity (Figure 1.3) [80-82]. It has been 
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shown in obese mice that increased ER stress in the hypothalamus suppresses 
leptin signalling. Conversely, reduced ER stress activates leptin signalling [80]. It 
has also been shown in obese animals and in cultured cell models that stimulation 
of inflammatory signalling pathways in the hypothalamus can reduce leptin 
activity, whereas inhibition of inflammatory signalling pathways activates leptin 
signalling [81]. 
Therefore, SOCS3, PTP1B, ER stress and inflammation might have direct effects 
on the attenuation of leptin signal activity in the hypothalamus, and the 
subsequent development of leptin resistance seen in obese individuals. 
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1.6.2 Gut–brain axis 
Besides the important function of the gastrointestinal tract in absorption and 
digestion of food, it is also considered a major endocrine organ [49]. The 
production of gut peptides aids digestive function, but lately it has been 
discovered that it also influences eating behaviour and appetite [83]. Many of the 
gut hormones participate in controlling appetite through their central action on 
the brain, mainly on the orexigenic NPY system and the anorectic melanocortin 
system in the hypothalamus which have a crucial role in energy balance [49]. 
Recent studies have concluded that manipulation of gut hormones might help in 
controlling energy balance in obese individuals by reducing appetite and inducing 
weight loss [83]. The first gut hormone that was shown to affect appetite was CCK; 
other hormones have subsequently been discovered, such as GLP-1, PYY and 
ghrelin [84]. 
 
1.6.2.1 Ghrelin 
Ghrelin is the only known gut hormone that increases food intake [85]. It is 
secreted by A cells located in the fundus of the stomach [86]. The concentration 
of ghrelin increases before each meal and decreases postprandially [84], which 
indicates its short-term effect in appetite regulation [85] through its stimulation 
of the hypothalamic arcuate nucleus and the production of anabolic NPY and 
AGRP [86]. The Tschop group showed that chronic administration of ghrelin in 
rodents results in continuous food intake and weight gain [87], so it seems that 
ghrelin also plays a role in regulating appetite and body weight in the long term 
[88]. 
 
1.6.2.2 Peptide YY (PYY) 
PYY is a 36-amino-acid peptide that is secreted by enteroendocrine L cells of the 
gut, located in the intestines and mostly concentrated in the ileum and colon. Two 
forms of PYY are released after meal ingestion, PYY(1-36) and PYY(3-36), which 
belong to the PP-fold peptide family [89]. PYY(3-36) binds to Y2 receptors on the 
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arcuate nucleus, increasing activity of the anorectic melanocortin system and 
suppressing activity of the orexigenic NPY system [89]. Studies have shown that 
peripheral administration of PYY(3-36) leads to a decrease in food intake in rodents 
and humans [90]. However, high levels of PYY(3-36) may cause nausea in dogs [91] 
and in humans [92]. Witte et al. concluded that the effect of PYY(3-36) in reducing 
food intake might be due to decreased gastric emptying and nausea [93]. 
 
1.6.2.3 Glucagon-like peptide 1 (GLP-1) 
GLP-1 is a peptide hormone consisting of 30 amino acids, and is produced in 
response to nutrient ingestion by enteroendocrine L cells located in the small and 
large intestines, but mostly distributed in the ileum and colon [89, 94, 95]. GLP-1 
is also produced centrally in the brain [96]. L cells are described as open-type 
epithelial cells that are in direct contact with ingested food in the intestinal lumen 
[97]. In addition, they are very close to the neurons and microvasculature of the 
intestine and are affected by neuronal signals and hormones [98, 99]. 
Proglucagon is a 160-amino-acid prohormone that is produced in 
enteroendocrine L cells and pancreatic  cells [100, 101]. GLP-1 is synthesized by 
posttranslational processing of proglucagon by the prohormone convertase 1/3 
in L cells. Proglucagon gene expression is activated by -catenin in intestinal L 
cells. This activation is mediated by the transcription factor TCF-4 [102]. Variants 
of TCF-4 are associated with development of type 2 diabetes, indicating that GLP-
1 might be involved in the development of this disease [103]. 
 
GLP-1 forms 
There are multiple forms of GLP-1 present in the circulation, such as GLP-1 (1-37) 
and GLP-1 (1-36) amide, which are not biologically active. However, the bioactive 
forms GLP-1 (7-37) and GLP-1 (7-36) amide are the major circulating active forms 
of GLP-1. It is believed that the addition of the amide group to GLP-1 (7-36) amide 
is mediated by the enzyme peptidylglycine α-amidating monooxygenase, and this 
extends the half-life of active GLP-1 in the circulation [104]. 
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GLP-1 has a short half-life of 1–2 minutes in the circulation as it is rapidly broken 
down by the catalytic enzyme dipeptidyl peptidase IV (DPP-IV), which cleaves off 
the two NH2-terminal amino acids, thus forming the inactive metabolites GLP-1 
(9-36) amide or GLP-1 (9-37) [105]. DPP-IV is expressed in many cells and tissues 
including the intestines, kidneys, liver, lungs, CNS and pancreas. It is also 
expressed in endothelial cells lining the capillaries of the lamina propria, which 
are located close to the site of GLP-1 secretion. About two-thirds of the total 
amount of GLP-1 secreted is degraded by DPP-IV before entering the portal 
circulation. Further degradation is carried out in the liver, and only about 10–15% 
of intact GLP-1 reaches the systemic circulation [99, 101, 106]. The major route of 
GLP-1 clearance is through the kidneys [101]. 
 
Regulation of GLP-1 secretion 
In humans, GLP-1 is released rapidly into the circulation after nutrient ingestion 
and oral glucose administration, but not intravenous glucose administration [107, 
108], and the secretion depends on caloric intake [94]. GLP-1 is secreted in a 
biphasic pattern postprandially, an early short phase starting within 10–15 
minutes, followed by a late longer 30–60-minute phase [107]. Ingested 
carbohydrate and fat have been shown to be especially strong stimulators of GLP-
1 secretion [109]. In addition, direct administration of fat and glucose to the 
intestinal lumen also stimulates GLP-1 secretion [110, 111]. 
The early and rapid release of GLP-1 cannot be explained by direct interaction 
between the ingested nutrients and L cells, as L cells are dominantly present in 
the distal gut, and nutrients require more than half an hour to reach this part of 
the intestine [97, 112, 113]. Therefore, it is suggested that the early postprandial 
peak of GLP-1 is induced indirectly by the neuroendocrine pathway, unlike the 
later peak that is attributed to direct contact of luminal nutrients with L cells 
[111]. Evidence supports the suggestion that the nervous system is involved in 
the early peak of GLP-1 secretion. Researchers have found that stimulation of rat 
L cells is prevented by bilateral subdiaphragmatic vagotomy. However, GLP-1 
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secretion is increased with direct activation of the efferent coeliac branch [110]. 
In vitro studies have shown that acetylcholine has a stimulatory effect on L cells 
in humans and rodents [98, 114]. In addition, in rodents, duodenal nutrients fail 
to increase GLP-1 secretion after infusion with atropine and pirenzepine [98]. 
Somatostatin is an intestinal neuroendocrine hormone that has been found to 
inhibit GLP-1 secretion. In vivo studies have shown that infusion of somatostatin-
14 inhibits GLP-1 secretion from L cells in both humans and rats [115, 116]. 
Leptin is also reported to have stimulatory effects on GLP-1 secretion. 
Administration of leptin to mice increases GLP-1 secretion. The same effect is 
observed in human L cells in vitro [117, 118]. Both basal and postprandial GLP-1 
concentrations are reduced in obese subjects [119, 120]. In addition, increased 
leptin secretion and leptin resistance are observed in obese patients. Thus, it is 
hypothesized that as leptin stimulates L cells, leptin resistance may be responsible 
for the reduction in GLP-1 secretion reported in obese patients [118]. 
 
GLP-1 receptors 
The GLP-1 receptor (GLP-1R) is a class-2 G protein-coupled receptor [121]. In the 
early 1990s, Bernard Thorens cloned and sequenced human and rat GLP-1R from 
their pancreatic islet libraries. Both receptors consist of 463 amino acids [122, 
123]. Thorens also discovered two lizard peptides, exendin-4 and exendin 9-39, 
that can bind to human GLP-1. Exendin-4 shares 53% structural homology with 
mammalian GLP-1, and acts as a potent agonist; it differs from GLP-1 in that it is 
more stable, as it is not degraded by DPP-IV. Exendin 9-39 is a human GLP-1 
antagonist [123, 124]. Liraglutide is a synthetic GLP-1 derivative of exendin-4, and 
has closer homology (97%) to human GLP-1 [125]. The GLP-1 receptor is 
distributed in the pancreas, central and peripheral nervous system, heart, 
stomach, kidneys, gastrointestinal tract and adipose tissue [101, 126-128]. 
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GLP-1 and appetite 
Like other gastrointestinal secreted hormones, GLP-1 is involved in controlling 
nutrient intake. The presence of GLP-1 receptors in the brain structures which are 
known to be involved in controlling food intake, including the PVN and dorsal 
medial nucleus of the hypothalamus (DMH), and area postrema and NTS in the 
brainstem, indicates the important action of GLP-1 in regulating energy balance 
[127]. Studies indicate that central administration of exogenous GLP-1 inhibits 
food intake in rats, which supports the anorexigenic effect of this peptide [129, 
130]. GLP-1 infusions increase satiety and decrease energy intake in lean and 
overweight subjects [131]. 
Intracerebroventricular injection of GLP-1 has been shown to attenuate the action 
of the potent orexigenic agents NPY and melanin-concentrating hormone (MCH) 
in rats [132]. Furthermore, a lesion in the arcuate nucleus that contains the cell 
bodies of the NPY neurons results in complete inhibition of the anorectic action of 
GLP-1 in rats [133]. These results suggest that interaction between the anorectic 
peptide GLP-1 and the orexigenic peptides NPY and MCH may modulate the 
activity of feeding centres [134]. The anorectic effect of GLP-1 may be mediated 
either indirectly by acting in a paracrine-like fashion on peripheral GLP-1 
receptor expressed in the intestinal vagal afferent neurons, or acting directly on 
central GLP-1 receptors after crossing the BBB [135, 136]. Intravenous 
administration of exendin-4 has also been shown to cross the BBB in mice [137]. 
Moreover, GLP-1 hormone may also indirectly affect food intake by reducing 
gastric emptying. Subsequently, stimulation of the satiety centre and a reduction 
in food intake are likely [138]. It is reported that postprandial GLP-1 levels are 
reduced in obese subjects; however, the mechanism by which obesity decreases 
GLP-1 levels is not, as yet, clear [139, 140]. 
 
GLP-1 and glucose homeostasis 
Another important function of GLP-1 is its incretin effect. Gastric inhibitory 
polypeptide and GLP-1 are considered potent incretin hormones that are capable 
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of increasing insulin secretion and reducing blood glucose in response to oral 
nutrient intake. It is estimated that after oral glucose ingestion, about 50–70% of 
total insulin secretion is induced by this incretin effect. GLP-1 stimulates the 
biosynthesis and production of insulin from pancreatic beta-cells [106]. The 
incretin effect has been demonstrated by comparing the insulin response to oral 
and intravenous administration of glucose, with adjustment of an intravenous 
infusion of GLP-1 to produce the same peripheral blood glucose concentrations 
[141]. In a healthy subject, oral administration has been shown to cause a two- to 
threefold greater insulin response than the intravenous route [101]. Besides the 
incretin effect, GLP-1 plays a role in maintaining pancreatic beta-cell mass by 
stimulating beta-cell proliferation and inhibiting apoptosis [142, 143]. In the 
gastrointestinal tract, GLP-1 inhibits acid secretion. In addition, it reduces the 
increase in blood glucose levels associated with food ingestion by slowing gastric 
emptying. Other functions of GLP-1 related to normalizing blood glucose are 
inhibition of glucose production by the liver, inhibition of glucagon secretion, and 
an increase in insulin sensitivity [144-146]. 
The incretin effect seems to be very weak in patients with type 2 diabetes, and 
GLP-1 has been shown to be significantly reduced in some diabetic patients [147, 
148]. Exendin-4, acting as a GLP-1 agonist, is currently used to treat type 2 
diabetes. It lowers blood glucose without causing hypoglycaemia, increases 
insulin secretion by improving beta-cell function and decreases glucagon 
secretion. However, nausea and vomiting are common side effects of exendin-4; 
nausea occurs in approximately 50% of patients, and about 4% of them 
discontinue the treatment because of intolerable nausea [61, 149]. Studies in rats 
have shown that the effect of peripheral exendin-4 on causing nausea does not 
require vagal afferent pathways, as subdiaphragmatic vagotomy does not inhibit 
the nausea effect produced by chronic peripheral exendin-4 administration. 
Therefore, exendin-4 seems to induce nausea by penetrating the BBB, and 
subsequent activation of GLP-1R in the brain, mostly in the NTS [150]. 
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GLP-1 and adipose tissue 
GLP-1 has an important role in lipolysis and fatty acid synthesis; it has been 
shown to cause lipolysis in isolated rat adipocytes. It also stimulates fatty acid 
synthesis in omental adipose tissue cultures at its normal circulating 
concentrations. In 3T3-L mouse adipocytes, GLP-1 has been shown to induce 
insulin-dependent glucose uptake and stimulate glucose transporter 1 and 4 
protein levels [151]. 
In rats, GLP-1 decreases macrophage infiltration and secretion of pro-
inflammatory cytokines, such as interleukin 6 (IL-6) and tumour necrosis factor-
 (TNF-), in adipose tissue. Therefore it may help to inhibit the systemic 
inflammation associated with obesity and insulin resistance [152]. Some studies 
suggest that GLP-1 and GLP-1 agonists may regulate adipokine secretion. GLP-1 
inhibits visfatin secretion from differentiated 3T3-L1 adipocytes [153]. Also, 
exendin-4 has been shown to stimulate adiponectin secretion, via a protein kinase 
A pathway in vitro, and to improve cellular insulin sensitivity [154]. In an in vivo 
study, central infusion of exendin-4 in lean and obese male rats resulted in 
reduced body weight in both lean and obese groups; however, this was 
accompanied by decreased plasma leptin concentrations only in lean, and not in 
obese, rats [155]. 
 
1.7 Ethnicity and GLP-1 secretion 
The rapid increase in global obesity prevalence has increased the need to 
understand the aetiology of obesity in order to choose the best approaches for 
managing and preventing this disease. One causative factor of this phenomenon 
might be related to differences in satiety and incretin hormone secretion among 
different ethnic groups. As mentioned earlier, low postprandial GLP-1 secretion 
in obesity and type 2 diabetes might contribute to these disorders [140, 147]. 
GLP-1 analogue and DPP-IV inhibitor agents have started to be used worldwide 
as antihyperglycaemic medications and to help in reducing weight [156]. 
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Obesity and type 2 diabetes prevalence is higher in African Americans than in 
Caucasians, both among adults and adolescents. In a study of 42 severely obese 
Caucasian and African American adult females, evaluating insulin and GLP-1 
secretion in response to an oral glucose tolerance test (OGTT), it was found that 
fasting and postprandial insulin and GLP-1 secretions were higher in the African 
Americans than in the Caucasians. Thus the GLP-1 response might be one 
contributing factor related to the high prevalence of obesity, hyperinsulinemia 
and type 2 diabetes in African Americans [157]. 
Another study of 49 obese Caucasian and African American adolescents reported 
lower postprandial GLP-1 levels in African Americans, supporting the previous 
finding and a role for lower GLP-1 levels being related to the predisposition of 
obese African Americans to type 2 diabetes [158]. 
Similarly, a study in normal-weight, healthy or diabetic young Japanese found that 
intact postprandial GLP-1 concentrations remained low and did not peak in either 
the diabetic or non-diabetic groups after either OGTT or a meal challenge [159]. 
Supporting this result, DPP-IV inhibitors were found to be more effective in 
lowering HbA1c in Japanese diabetic patients than in non-Japanese diabetic 
patients [160]. In addition, GLP-1 analogues were also found to be more efficient 
in lowering HbA1c in Asians than in non-Asians [161]. 
 
1.8 Glucose-dependent insulinotropic polypeptide (GIP) 
GIP was the first incretin hormone identified and was previously known as gastric 
inhibitory polypeptide, related to its ability to inhibit gastric acid secretion in dogs 
[162]. However, subsequent studies revealed its ability to also stimulate insulin 
secretion in response to nutrient ingestion in humans [163]. GIP is released from 
enteroendocrine K cells located mostly in the duodenum and proximal jejunum 
[95]. Glucose and fat are potent stimulators of GIP secretion in human subjects, 
leading to rapid release of GIP that reaches a peak in 15–30 or 30–45 minutes 
after oral ingestion of glucose or intraduodenal infusions of fat [164-166]. GIP 
secretion is proportional to the amount of calories ingested [94]. Furthermore, it 
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is the rate of intestinal glucose absorption rather than the mere presence of 
nutrients in the intestine that stimulates GIP production and an increase in GIP 
levels [167]. Thus, GIP secretion is reduced as a result of intestinal malabsorption, 
or after intraduodenal administration of pharmacologic agents reducing nutrient 
absorption [168, 169]. Patients with type 2 diabetes have been found to have a 
normal GIP plasma level [170]; however, the incretin effect of GIP is diminished 
and cannot be remedied by administration of exogenous GIP [171, 172]. 
Like GLP-1, GIP exerts its incretin effects though specific, glycosylated receptors 
belonging to the secretin B-family of G protein-coupled receptors [173]. Besides 
the presence of GIP receptors in pancreatic islets, GIP receptors are also found in 
adipose tissue, gut, several regions of the brain, testis, pituitary, lung, heart, 
vascular endothelium and bone [174]. 
 
1.9 Endogenous DPP-IV activity 
DPP-IV, also known as CD26, is a membrane-associated peptidase that consists of 
766 amino acids and is expressed in different tissues. In addition to the 
membrane-bound species, it is also found in a soluble form in the circulation [175-
177]. The biological role of DPP-IV relates to both its enzymatic and non-catalytic 
functions. DPP-IV interacts with various ligands such as ADA, caveolin-1, kidney 
Na+/H+ ion exchanger 3, thromboxane A2 receptor, CXCR4 and fibronectin, 
allowing it to mediate different processes including immune regulatory function, 
such as stimulating T-cell activation [178-182]. The catalytic role of DPP-IV is 
exhibited both by the membrane-spanning form of the molecule and by the 
circulating soluble form. DPP-IV breaks down bioactive peptides with an amino-
terminal proline or alanine at position 2 [183, 184]. GIP and GLP-1 hormones are 
peptides with an alanine at position 2 that renders them ideal putative substrates 
for the aminopeptidase DPP-IV [185]. Thus this enzyme plays an indirect role in 
regulating glycaemia through inactivation of incretin hormones [105]. DPP-IV 
inhibitor is used as a therapeutic drug for type 2 diabetes as it prevents the 
inactivation of GLP-1 by DPP-IV. In October 2006, the Food and Drug 
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Administration approved sitagliptin as the first selective DPP-IV inhibitor, for use 
alone or in combination with metformin or thiazolidinedione to treat type 2 
diabetes [186]. 
 
1.10 Glucagon 
Glucagon is a 29-amino-acid peptide hormone that is released from pancreatic α 
cells [187]. This hormone plays a critical role in the regulation of glycaemia. It 
opposes the action of insulin during hypoglycaemia by stimulating hepatic 
glucose synthesis and mobilization, thereby increasing blood glucose 
concentrations [188-190]. Insulin, GLP-1 and somatostatin inhibit glucagon 
production. Interestingly, the incretin hormones GIP and GLP-1 have different 
effects on glucagon secretion, with GIP stimulating but GLP-1 inhibiting glucagon 
secretion [191-194]. Using isolated islets, it has been demonstrated that the 
inhibitory effects of GLP-1 are not associated with augmentation of insulin or 
somatostatin secretion, but involve PKA signalling [193]. 
 
1.11 Non-surgical treatment of obesity 
1.11.1 Diet 
As energy imbalance is one of the major causes of weight gain, the treatment of 
obesity should be as simple as reducing eating and increasing physical activity! 
Different dietary approaches are used for weight loss [195]. Low-calorie diet 
(LCD, 800–1000 kcal/day), very low-calorie diet (VLCD, 450 to < 800 kcal/day) 
and meal replacement (200–400 kcal/day) therapies are common dietary 
approaches to reduce excess weight [196]. With VLCD, in the first 6 months, 
weight loss is about 2 kg per week; this then decreases to 0.8 kg per week over 
the next 6 months [196]. However, rapid weight regain is reported at 12 months 
[197]. Thus, diet alone appears to be ineffective in the long-term maintenance of 
weight loss. 
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1.11.2 Physical activity 
Exercise is commonly considered an important component of a weight-loss 
programme. However, studies have shown that exercise alone is ineffective as a 
means of weight loss, and dietary changes seems to be more effective for this [198, 
199]. Exercise, however, is the best way of preserving lean body mass, which is 
often lost when following LCD [200]. 
 
1.11.3 Behavioural therapy 
Behavioural treatments help obese individuals to change their behavioural 
pattern by developing adaptive thinking, eating and exercise habits that enable 
them to reduce their weight and avoid regaining weight. People who add 
behavioural treatment to caloric restriction and exercise may expect to lose about 
5% to 10% of their total weight in about 4 to 6 months [201]. 
 
1.11.4 Pharmacotherapy 
There are two modes of action of weight-loss drugs, reducing nutrient absorption 
or reducing food intake. Orlistat is the most popular drug for treating obesity. It is 
a hydrogenated derivative of a bacterial lipase inhibitor which inhibits pancreatic 
lipase, thus reducing triglycerides. The digestion of about 30% of orally ingested 
triglycerides is inhibited by Orlistat. This drug has undesirable effects, such as 
faecal urgency, incontinence and malabsorption of fat-soluble vitamins. 
Moreover, this drug has not been effective in long-term (more than 1 year) studies 
[202]. 
Sibutramine is a phenethylamine that selectively blocks the reuptake of 
noradrenaline, serotonin (5-HT) and, to a lesser extent, dopamine, and 
subsequently reduces food intake. The drug was withdrawn from use in Europe 
in 2010 due to its related cardiovascular risks [203]. 
Currently, gut peptides (PYY, GLP-1, ghrelin and oxyntomodulin) are novel targets 
for developing new obesity treatments. Exendin-4 and liraglutide have been 
shown to produce ~3 kg reduction of body weight in 26 weeks [204]. However, 
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nausea is the main side effect of these synthetic GLP-1, which prevents the 
administration of higher doses that might have greater effects on weight loss 
[205]. PYY infusion has been found to lower the orexigenic effect of ghrelin by 
decreasing its level and reducing hunger and food intake in obese and lean 
individuals [206]. 
Combination of two or more of the gut peptides may lead to more effective weight 
loss. PYY and GLP-1 have an additive effect on reducing food intake, both when 
administrated peripherally in mice, and after intravenous infusion in humans 
[207]. 
 
1.12 Bariatric surgery 
Today, bariatric surgery is known as the most effective way of treating obesity 
and its associated comorbidities. It produces significant weight loss that is 
maintained long term, improves metabolic abnormalities, and subsequently 
achieves complete resolution of insulin resistance, diabetes, dyslipidaemia, 
hypertension and obstructive sleep apnoea in the majority of patients [208]. The 
exact mechanism(s) by which bariatric surgery produces weight loss is still not 
fully understood. 
Patients that are eligible for bariatric surgery include morbidly obese (BMI 
greater than 40 kg/m2) or obese patients with a BMI of more than 35 kg/m2, with 
serious comorbidities (NICE guidelines, 2006). Several different types of bariatric 
surgery are currently available, and they have been classified into different types: 
restrictive, malabsorptive and a combination of both [209]. The most common 
types performed are restrictive and a combination of malabsorptive and 
restrictive (Figure 1.4). 
Restrictive procedures involve decreasing the stomach size, thereby reducing the 
amount of food intake by inducing early satiety. Gastric band (GB), a reversible 
procedure which involves placing a band around the upper part of the stomach 
below the gastro-oesophageal junction to reduce stomach capacity [210], and 
sleeve gastrectomy (SG) which involves excision of 70–80% of the greater 
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curvature, creating a narrow stomach tube, are examples of the restrictive type of 
weight-loss procedure [211, 212]. 
Malabsorptive procedures create a short bowel syndrome by bypassing most of 
the absorptive part of the small intestine, thereby preventing food from contact 
with crucial absorptive points of the intestinal tract. Jejunoileal bypass is an 
example of a malabsorptive procedure that achieves remarkable long-term 
weight loss. However, because of multiple significant complications in the 
majority of patients, it has fallen into disrepute and is no longer used [210]. 
A combination of restrictive and malabsorptive procedures leads to decreased 
food intake by decreasing stomach size. Roux-en-Y gastric bypass (RYGB) is an 
example of a restrictive/malabsorptive procedure and is the most common and 
effective weight-loss operation in current use. In RYGB, a small stomach pouch of 
approximately 30 ml is created and connected to the small intestine. The rest of 
the stomach (approx. 400 ml) is bypassed. The small intestine is divided 
approximately 45 cm below the lower stomach outlet and is re-arranged into a Y-
configuration, enabling outflow of food from the small upper stomach pouch via a 
‘Roux limb’. The Roux limb is constructed using 80–150 cm (31–59 in) of the small 
intestine, preserving the rest of it for absorbing nutrients. The patient will 
experience very rapid onset of the stomach feeling full, followed by a growing 
satiety (or ‘indifference’ to food) shortly after the start of a meal [210]. 
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1.12.1 Weight loss after bariatric surgery 
Non-surgical treatment and bariatric surgery are the usual obesity treatment 
options. The non-surgical option includes low caloric intake, increasing physical 
activity, behavioural therapy and different pharmacological treatments. Many 
studies have demonstrated the efficacy of bariatric surgery in achieving long-term 
and greater body weight loss, compared with non-surgical treatment [213]. A 
randomized controlled trial showed that at 2 years, laparoscopic adjustable GB 
resulted in a greater weight loss, with an average of 21% of initial weight lost, 
while the non-surgical treatment resulted in only 5.5% of initial weight lost [214]. 
A meta-analysis reported a mean percentage of excess weight loss (EWL) 2 years 
after surgery of 61.2% for all bariatric procedures, ranging from 47.5% for GB to 
61.6% for RYGB [215]. Greater weight loss was achieved by the RYGB procedure 
than by GB [216]. A 10-year follow-up of bariatric surgery reported a mean weight 
loss of 25% for RYGB, and 13.2% for GB. Although greater weight loss is seen with 
the RYGB procedure, both surgeries maintain long-term weight loss that may last 
beyond 10 years [217]. 
Several studies have shown that SG and RYGB achieve a similar amount of weight 
loss at 6, 12 and 18 months [218, 219]. However, there is still insufficient data 
with regards to the long-term weight-loss effect of SG [220]. 
Although both GB and SG are considered constrictive types of bariatric surgery, 
SG results in greater weight loss than GB. SG involves resection of a great part of 
the gastric body and antrum where the ghrelin-secreting mucosa is located, and 
thus attenuates the orexigenic effect of ghrelin [221]. 
 
1.12.2 Metabolic advantages of bariatric surgery 
Bariatric surgery is currently accepted as a metabolic surgical intervention. 
Diabetes resolution occurs in 76.8% of patients, and diabetes improves in 86.6% 
of patients following a bariatric procedure [215, 216]. Moreover, long term, 10 
years after bariatric surgery, diabetes resolution has also been reported in 82.9% 
of patients [210]. However, the type of surgery results in different outcomes: 
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83.7% diabetes resolution is observed after RYGB, whereas 47.9% is observed 
after GB. Bypass techniques act more efficiently in terms of improving insulin 
sensitivity and secretion, especially very early after surgery (first week), even 
before obtaining a significant weight loss. The SG procedure also induces rapid 
metabolic changes postoperatively. Fasting serum glucose and insulin are 
reduced significantly 5 days after SG [222]. However, despite the comparable 
weight loss achieved by RYGB and SG procedures, better and more durable 
glycaemic control is seen 2 years after RYGB, but not SG [223]. Thus, the best effect 
on controlling glycaemia is obtained by the RYGB technique [224]. 
Unlike RYGB and SG, an improvement in insulin sensitivity and glycaemia is only 
apparent 6 months after GB surgery, which indicates that the metabolic 
improvement seen after GB is mostly secondary to weight loss [225]. 
Improvement in lipid profile had been reported in 20% of patients after bariatric 
surgery [226]. One year after RYGB, total cholesterol levels are reduced by 16%, 
triglyceride by 63%, low-density lipoprotein (LDL) cholesterol by 31%, very low-
density lipoprotein cholesterol by 74%, and total cholesterol/high-density 
lipoprotein (HDL) cholesterol risk ratio by 60%; HDL cholesterol concentrations 
increase by 39%. Moreover, within 1 year postoperatively, 82% of patients 
discontinue their lipid-lowering medications. This improvement has been 
observed at 3 months after RYGB and may last up to 1 year [227]. Moreover, a 
recent study showed that significant improvement in lipid profiles occurs as early 
as 2 weeks after RYGB and SG [228]. 
A retrospective analysis by Zhang et al. reported that there is improvement in 
lipid profiles after an SG procedure, especially in HDL cholesterol and 
triglycerides, with no change in LDL and total cholesterol [229]. It was also found 
that the improvement in HDL and triglyceride seen after laparoscopic SG is 
comparable to that seen after RYGB [230]. 
GB has also been shown to significantly reduce triglycerides and increase HDL 
cholesterol at 1 and 2 years postoperatively, and this improvement may persist 
for up to 5 years [231]. Thus, it seems that the RYGB procedure is better in terms 
of improving all the variables of lipid profile (triglycerides, HDL, LDL and total 
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cholesterol) and is more efficient in treating hyperlipidaemia [229]. 
Hypertension is another component of metabolic syndrome. Improvement in 
hypertension has been reported in 27% of patients after bariatric surgery [226]. 
A meta-analysis showed that 78.5% of all patients undergoing bariatric surgery 
have resolution or improvement in their hypertension over the first and second 
years postoperatively, but it is not sustained beyond the second year [215]. The 
reduction in hypertension after bariatric surgery appears to reach a plateau 
around 2 years postoperatively [232]. 
Obstructive sleep apnoea (OSA) is a common condition associated with morbid 
obesity. This condition results from elevation of upper airway collapse that is 
associated with ineffective respiratory efforts during sleep. Obstruction of the 
upper airway structures is due to excessive fatty tissue and its laxity, a condition 
that is associated with morbid obesity [233]. Weight loss is the most effective 
management of OSA. Bariatric surgery has been found to be very effective in the 
resolution of OSA [233]. After laparoscopic RYGB, patients with OSA show 
improvement from the first month postoperatively, and some discontinue the use 
of continuous positive airway pressure (CPAP) by the sixth month following 
surgery. Weight loss leads to a reduction in upper airway adipose tissue and 
improves the pharyngeal neuromuscular control, and subsequently decreases 
upper airway obstruction [234]. 
 
1.12.3 Hormonal changes after bariatric surgery 
The advantageous effects of bariatric surgery in terms of weight loss and 
metabolic improvement are due, at least in part, to alteration in gut hormones and 
adipokines [235]. Plasma visfatin decreases and adiponectin increases 3 months 
after an RYGB procedure [236]. RYGB induces an acute decrease in leptin, 
improvement in insulin sensitivity and increase in postprandial insulin GLP-1 and 
PYY that are sustained for at least a year, leading to suppression in appetite and 
long-term weight loss [235, 237, 238]. While immediate improvement in glucose 
homeostasis following RYGB independent of weight has been explained by the 
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increased insulin response and enhanced insulin sensitivity caused by 
exaggerated GLP-1 [235, 239], the exact mechanism by which RYGB alters gut 
hormone secretion is still uncertain. However, it is hypothesized that bypassing 
the proximal part of the small intestine causes rerouting of ingested food and 
digestive fluid, and as a result changes the gastrointestinal relationship with 
nutrients. Supporting this theory, the beneficial metabolic effects of purely 
restrictive bariatric procedures, such as GB, usually appear later, following weight 
loss. These procedures do not produce acute improvement of postprandial 
glucose metabolism or gut hormones. Rerouting undigested food causes rapid 
contact between ingested nutrients and L cells located in the small intestine 
(ileum) at a higher density, and thus directly stimulates these enteroendocrine 
cells without stimulating the bypassed foregut [240]. 
Therefore, the RYGB technique induces changes in gastrointestinal endocrinology 
in a way that reduces overeating and improves glucose homeostasis, by increasing 
secretion of incretin and satiety hormones including GLP-1, PYY and 
oxyntomodulin [237, 240]. 
RYGB may also produce increased GLP-2, a gut repair hormone, and subsequent 
intestinal mucosal crypt cell proliferation. Furthermore, a study in rats showed an 
elevation in the number of L cells after gastric bypass and concluded that the 
elevation in PYY and GLP-1 levels seen after this procedure may be due to the 
increased L-cell population [241, 242]. 
The hypothesis that there is metabolic improvement pertaining to increased GLP-
1 secretion after RYGB has been argued, as such metabolic advantages can be seen 
only modestly after subcutaneous administration of GLP-1 receptor agonist, 
despite resulting in equal levels of circulating GLP-1. 
It is thought that the effects of endogenous GLP-1 are mediated by activation of 
local afferent sensory nerve fibres (vagal nerve) that then activate certain regions 
in the NTS and hypothalamus which influence insulin and glucose metabolism. 
This effect is absent with exogenous GLP-1 [240]. 
Like RYGB, SG may also have an acute effect on appetite and glucose metabolism 
related to early hormonal changes. Ghrelin secretion decreases, whereas PYY and 
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GLP-1 increase acutely following SG. Thus SG is no longer considered a purely 
constrictive type of bariatric surgery [243-245]. The mechanism by which SG 
results in acute alteration in gut hormones is as yet unclear. However, ghrelin 
reduction is due to gastric fundus removal [244]. 
This alteration in gut hormones is not found after a GB procedure. It has been 
reported that postprandial GLP-1 and PYY levels are increased after RYGB but not 
GB surgery [246, 247]. 
 
1.12.4 Complications of bariatric surgery 
High rates of complications, approaching 40%, were reported in 2001 following 
bariatric surgical treatment of obesity. These complications usually vary 
according to the procedure performed [248]. 
 
1.12.4.1 Roux-en-Y gastric bypass 
Stomal stenosis: The anastomotic stenosis rate is 6–20% following RYGB [249]. 
It usually occurs several weeks after surgery, and patient presents with nausea, 
vomiting and gastroesophageal reflux; diagnostic and therapeutic endoscopy is 
used to diagnose the case, and treat it with balloon dilation [250, 251]. Stomal 
stenosis is more frequent after laparoscopic RYGB than open RYGB [252]. 
 
Marginal ulcer: Marginal ulceration has been observed in 1–16% of patients 
[253]; it occurs close to gastrojejunostomy. Nausea and vomiting, pain, bleeding 
and perforation are common complaints of this condition [254]. Possible causes 
of ulceration include: ischaemia at the anastomotic site that results in inadequate 
tissue perfusion, the presence of a nonabsorbable suture or staple around the 
area, jejunal injury from excess acid exposure, usage of nonsteroidal anti-
inflammatory drugs, and smoking. Upper endoscopy is used to diagnose marginal 
ulcer [253, 255-257]. 
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Cholelithiasis: Gall stones are a common complication of RYGB; it has been 
reported that as many as 38% of patients develop cholelithiasis within 6 months 
of surgery, and symptoms appear in 41% of such patients [258]. Symptomatic 
patients present with severe right upper quadrant abdominal pain associated 
with nausea and vomiting [259]. It is believed that developing gallstones is 
associated with rapid weight loss [260]. Abdominal ultrasound is used to 
diagnose cholelithiasia [261]. 
 
Internal hernias: The Roux-en-Y technique involves the creation of potential 
internal spaces through which herniation of the small bowel may occur [262]. 
Internal hernia incidence has been reported in 0–5% of patients undergoing 
laparoscopic bariatric surgery [252, 263]. Internal hernia can be complicated by 
small bowel obstruction [262]. Patients present with abdominal pain 
accompanied by nausea and vomiting. A CT scan of the abdomen and pelvis is used 
to diagnose internal hernia [264]. 
 
Dumping syndrome: Dumping syndrome can be found in up to 50% of patients 
who have undergone RYGB and is associated with ingesting greater amounts of 
simple carbohydrates. Dumping may help with losing weight in part by making 
the patient modify his/her eating habits [265]. 
Dumping syndrome can be classified into early and late: 
Early dumping syndrome — Early dumping syndrome occurs early 
postprandially, usually within 15 minutes. It is most likely due to rapid food 
emptying into the small intestine. As a result of hyperosmolality of the food, fluid 
shifts rapidly from the plasma into the bowel; subsequently, hypotension and a 
sympathetic nervous system response occur. Patients often experience 
abdominal pain, nausea and tachycardia [266]. Avoidance of foods containing 
simple carbohydrates and replacing them with high-fibre, complex carbohydrates 
and protein-rich foods is recommended. Changing eating habits, such as eating 
small, frequent meals, and leaving a 30-minute interval between intake of solids 
and liquid are also advised. Early dumping usually disappears 3 months after 
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RYGB without requiring medical interference [265]. 
Late dumping syndrome — Late dumping syndrome occurs 2–3 hours 
postprandially and is associated with hyperglycaemia followed by insulin 
response leading to hypoglycaemia. Dizziness, fatigue, diaphoresis and weakness 
are presentations of late dumping. Similar management to that used for early 
dumping syndrome is applied to late dumping [265]. 
 
Nutritional deficiency: Nutritional depletion is common in severely obese 
individuals and can be aggravated following RYGB surgery due to reduced food 
intake and decreased absorption of different micronutrients, in particular iron, 
vitamin B12, folate, calcium and thiamin, and this deficiency can lead to various 
conditions, mostly anaemia and neural dysfunction. Therefore, multivitamin and 
mineral supplementation is crucial after RYGB surgery [267]. However, even with 
supplementation, patients still experience depletion in some micronutrients 
[268]. 
 
1.12.4.2 Gastric band (GB) 
Stomal obstruction: Stomal obstruction is a potential complication that can 
occur early after GB surgery in about 14% of patients. The causes of obstruction 
include: incorporation of excess perigastric adipose tissue, using a band with 
insufficient diameter to include the whole thickness of the tissue, or developing 
oedema in tissue. The patient usually complains of nausea, vomiting and inability 
to tolerate food intake. The diagnosis is confirmed with an upper gastrointestinal 
barium meal and oesophagogastroscopy that illustrate obstruction and no 
passage of contrast beyond the band [269-271]. 
 
Port infection: The incidence of port site infection is between 0.3% and 9% in GB 
patients. The infection is usually treated with surgical removal of the port; once 
the infection subsides, the port is reimplanted [272, 273]. 
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Band erosion: Band erosion of the stomach wall is a late complication that has 
been reported in about 7% of GB patients. Erosion can be caused by stomach wall 
ischaemia that arises from an excessively tight band, mechanical trauma 
contributing to the usage of band buckle, or thermal trauma from electrosurgical 
energy sources when placing the band; infection, stopping losing weight, and 
nausea and vomiting are clinical signs associated with this condition [274, 275]. 
 
Oesophageal dilatation: Oesophageal dilatation has been reported in up to 10% 
of patients. This condition is known as pseudoachalasia syndrome and may arise 
when the band is overinflated or on ingesting excessive amounts of food [276]. 
 
1.12.4.3 Sleeve gastrectomy (SG) 
Stenosis: Stenosis can cause gastric outlet obstruction. Incidence of this 
complication varies from 0.7% to 4%. Patients usually present with dysphagia, 
vomiting, dehydration and an inability to tolerate food intake. Endoscopy is used 
to diagnose this condition [277, 278]. 
 
Gastric leaks: Gastric leaks are considered a serious complication of SG that have 
been reported in up to 5.3% of patients. Fever, tachycardia and tachypnoea are 
usually experienced by patients. Diagnosis is established by upper 
gastrointestinal radiograph [279]. 
 
Reflux: Gastro-oesophageal reflux has been reported in 47% of SG patients. The 
classical symptoms of this case are burning pain, heartburn and regurgitation. It 
is usually treated with a proton pump inhibitor [279, 280]. 
 
1.13 Endoscopic weight-loss surgery 
An endoscopic approach for obesity management has developed as a result of an 
attempt to produce some of the anatomical manipulations and physiological 
effects of traditional weight-loss surgery with a less invasive and incisionless 
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procedure as well as fewer perioperative complications and a shorter recovery 
time [281]. 
Other indications for performing an endoscopic procedure are considering such 
intervention in individuals with early-stage obesity who do not require invasive 
bariatric surgery, in morbidly obese individuals before proceeding with invasive 
bariatric surgery to lower peri- and postoperative risks associated with obesity, 
and in patients with metabolic disorders, in particular type 2 diabetes, as a 
primary surgical intervention [281]. 
As with bariatric surgery, the endoscopic technique can be constrictive, reducing 
gastric capacity by using a space-occupying object or gastric suturing or stapling, 
malabsorptive, creating malabsorption by preventing passage of ingested 
nutrients through the duodenum and the proximal part of the jejunum, or a 
combination of both [281]. 
 
1.13.1 Constrictive endoscopic methods 
1.13.1.1 Intragastric balloon 
This technique was one of the first endoscopic gastric restrictive procedures 
available. The first intragastric balloon was the Garren-Edwards bubble (GEB) 
that was mostly used in the United States during the 1980s. The Food and Drug 
Administration (FDA) approved GEB in 1985 [282]. 
The bioenteric intragastric balloon (BIB) was first used in 1999. This technique of 
intragastric balloon has been widely studied worldwide. In spite of that, BIB has 
not been approved by the FDA and is not used in United States; it is approved and 
used in many other regions such as Europe, Australia, Canada, Mexico, India and 
several South American countries [281]. It is performed through placement of an 
intragastric adjustable silicone elastomer balloon with spherical shape, therapy 
which reduces gastric volume and enhances satiety. The balloon is then removed 
after about 3–6 months, after achieving the desirable weight, by using endoscopy 
with or without sedation. 
It has been shown that balloon treatment lasting for 6 months results in an 
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average weight loss of 15 kg [283]; however, the main concern related to such a 
technique is weight regain after balloon removal [284]. Moreover, although it 
carries less risk than invasive bariatric surgery, some complications are recorded 
following this procedure, such as gastric ulceration and erosion, oesophageal 
laceration and small bowel obstruction [282]. A retrospective study showed a low 
complication rate of about 2.8%, with EWL of 33.9% after BIB [285]. 
It has been reported that leptin decreases significantly at 6 months (at the time of 
balloon removal), whereas no significant change is seen in adiponectin, PYY or 
ghrelin after 6 months of having the intragastric balloon [286-288]. 
The Spatz adjustable balloon system (SABS) was introduced to overcome the 
limitations associated with BIB. The balloon volume can be adjusted while in the 
stomach and can be left in the stomach for 1 year; 36% and 48.8% EWL has been 
reported at 6 and 12 months, respectively [289]. A study was conducted to 
compare the 1-year effect on weight loss between BIB and SABS. In the BIB 
procedure, two balloons were used; the first balloon was placed for 6 months, 
after which it was extracted, and patients were given a 1-month holiday before 
placing the second balloon for another 6 months. It was concluded that both 
procedures yield similar weight loss [290]. 
A new technique used for intragastric balloon, a thin-walled, gas-filled, 
swallowable intragastric balloon (Obalon) has been designed recently. This 
technique does not require the use of upper gastrointestinal endoscopy to remove 
the balloon, and it allows gastric volume titration by swallowing additional 
balloons (up to three balloons). It has been reported that this procedure induces 
significant weight loss at 4, 8 and 12 weeks without serious complications; 
however, nausea and gastric pain are the most common side effects [291]. 
 
1.13.1.2 Endoscopic gastric stapling/suturing 
The endoscopic stapling procedure was designed to create a small and restrictive 
gastric cavity, therapy which induces early satiety and reduces food intake. 
Endoluminal gastric stapling was first done in 2007, and since then, different 
 54 
locations, techniques and devices have been used. In the beginning, it was tested 
in rats, and gastric plication of the greater curvature was found to induce greater 
weight loss than plication of the anterior wall [292]. Human trials showed a 
similar result, with 23% EWL after plication of the gastric anterior wall, and 53% 
EWL after plication of the greater curvature [293, 294]. 
 
Endoluminal vertical gastroplasty is one of the suturing techniques; it uses an 
EndoCinch device to create a continuous suture pattern from the proximal fundus 
to the terminal body, forming a narrow tube-like shape of the stomach [282]. 
 
Transoral gastroplasty (TOGA) is another endoluminal procedure that restricts 
stomach volume by creating endoscopic stapling of the lesser curvature; 24% 
EWL at 6 months is reported for this technique [294]. 
 
Transoral endoscopic restrictive implant system (TERIS) is a recent 
endoscopic technique that uses a permanent implant as a restrictor, with a 10-
mm orifice for food passage, and which is usually placed at the gastric cardia; the 
restrictor can be removed at any time. However, TERIS may result in serious 
complications such as gastric perforation or pneumoperitoneum [281]. 
 
Nausea, vomiting and pain are common side effects seen after gastric stapling 
[294]. It has been reported that reoperation is required for complications such as 
intractable nausea, total dysphagia or total gastric obstruction [293, 295, 296]. 
A new novel procedure has been used recently for weight reduction and is known 
as primary obesity surgery endoluminal (POSE); details of this procedure are 
mentioned in Chapter 4. 
 
1.13.2 Malabsorptive endoscopic methods 
Beside the weight-loss effect of endoluminal malabsorptive procedures, they have 
a positive effect on obesity-related metabolic disorders [281]. 
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1.13.2.1 Duodenojejunal bypass sleeve 
A duodenojejunal bypass sleeve is performed using endoluminal implants; a 60-
cm sleeve is placed in the duodenum to bypass the duodenum and proximal 
jejunum, thus allowing food passage without contact with the duodenum or 
biliary and pancreatic secretions. This therapy delays digestion and alters 
production of some gut peptides such as GLP-1 [282]. 
A trial on obese diabetic patients undergoing this technique showed a good result 
after 52 weeks, with improved glycaemia and 39% EWL [297]. 
 
1.13.2.2 Gastroduodenojejunal bypass sleeve 
This novel endoluminal approach is used in order to get physiological effects 
similar to those seen after gastric bypass bariatric surgery. The device is 120 cm 
long; it is placed in the stomach and extended through duodenum and jejunum 
endoscopy, and is then anchored at the gastroesophageal junction with 
endoscopic and laparoscopic techniques. This sleeve prevents nutrient 
absorption throughout the stomach, duodenum and jejunum [281]. 
A trial was conducted on 24 obese patients, of whom 12 were obese and 
underwent gastroduodenojejunal sleeve to assess the efficacy of this technique on 
weight loss as well as glycaemic control. Seventeen patients completed the trial, 
and evaluation at 12 weeks revealed 39.7% EWL, with complete resolution of 
diabetes in these patients and discontinuation of antihyperglycaemic medication 
[298]. 
  
 56 
1.14 Aims of this thesis 
The aims of this thesis were to: 
1- Investigate whether persistent nausea and vomiting symptoms after RYGB 
could be due to exaggerated systemic GLP-1 levels. 
2- Investigate whether GLP-1 may directly inhibit adipocyte leptin secretion. 
3- Compare a novel technique (POSE) with RYGB with regards to effective weight 
loss and induction of favourable metabolic and hormonal changes. 
4- Investigate whether obesity and insulin resistance are associated with 
decreased postprandial levels of GLP-1 in subjects of Arab origin. 
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Chapter 2 
 
Materials and 
Methods 
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2.1 Study population 
2.1.1 Patient recruitment 
Study 1: Prolonged nausea and vomiting after metabolic surgery 
Subjects were recruited from a bariatric clinic (North London Obesity Surgery 
Service, Whittington Hospital, London, UK) and by local advertising at University 
College London. Group 1 consisted of ten female patients with nausea and 
vomiting symptoms. These patients had undergone laparoscopic RYGB and were 
characterized by persistent nausea and vomiting that had started at least 1 year 
after having had the surgery and lasted for over 6 months. Endoscopies were done 
to exclude a mechanical cause for their symptoms, such as anastomotic ulcer or 
stomal stenosis (section 1.12.4.1). Group 2: ten patients without nausea and 
vomiting. These patients had undergone laparoscopic RYGB but reported no 
abnormally prolonged symptoms of nausea and vomiting. Age, gender, ethnicity, 
BMI and time of surgery were all matched with Group 1. Group 3: seven morbidly 
obese subjects from those awaiting bariatric surgery. Group 4: six 
overweight/obese subjects not scheduled for any surgery. Group 5: nine normal-
weight healthy subjects. The last couple of groups were recruited by local 
advertising. The treating surgeon referred the symptomatic patients for the study. 
The asymptomatic patients and those on a waiting list were contacted by phone 
and they agreed to participate in the study. 
Adipose tissue study 
Six non-diabetic morbidly obese patients undergoing laparoscopic bariatric 
surgery (gastric bypass, gastric sleeve or GB) were recruited from a bariatric clinic 
(North London Obesity Surgery Service, Whittington Hospital, London, UK). 
Morbid obesity was classified as BMI ≥ 40 kg/m2. 
 
Study 2: Comparison of primary obesity surgery endoluminal (POSE) and 
RYGB 
The surgeon explained both POSE and RYGB to patients awaiting weight 
reduction surgery, along with the risks and benefits of each of the procedures. 
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Patients were then allowed a period of time with the information on both 
procedures, to consider having either one of the surgeries. Following this, six of 
the patients agreed to undergo POSE, while the remaining majority preferred to 
go for RYGB. 
 
Study 3: Post-absorptive and postprandial GLP-1 concentrations in an 
obesity-prone population (Arabs) 
Twenty-seven healthy female subjects were recruited from the staff of the Anti-
Doping Lab, Doha, Qatar (ADLQ), of whom seven were obese, eight overweight 
and 12 normal weight. 
Exclusion criteria were patients on current treatment of warfarin, malignancy or 
terminal illness. 
The studies were approved by the national ethics committees. The studies that 
were carried out in London were approved by Whittington Health; the REC 
reference number is 12/LO/0625. The study in Doha was approved by the 
Institutional Research Board of the ADLQ (SCH-ADL-070). Written informed 
consent was obtained from all subjects. 
 
2.1.2 Demographic and anthropometric data 
Weight (kg) and height (m) were measured, and BMI was calculated. Blood 
pressure and pulse were measured using a digital monitor (Datex-Ohmeda 
Patient Monitor, GE Healthcare, UK). Patient information including demographic 
data (date of birth, gender, ethnicity), surgery type (gastric bypass, POSE), 
medical history, current medication, weight-loss history, history of any physical 
activity, smoking habits and alcohol consumption were obtained and recorded. 
 
2.1.3 Meal challenge test 
Patients were asked to attend the bariatric clinic after an overnight fast. Blood 
samples were drawn from an antecubital vein into one tube with no anticoagulant 
added (serum), one with EDTA as the anticoagulant, one with NaF as the 
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anticoagulant (for measurement of plasma glucose concentrations), and another 
with EDTA along with a DPP-IV inhibitor to prevent breakdown of the active form 
of GLP-1. Patients were asked to ingest a mixed meal (different number of calories 
according to each study), and blood was collected at 0 minutes (prior to meal) and 
at 30, 120 and 180 minutes after the meal. 
Blood samples were placed in a centrifuge (3000 rpm, 15 minutes, 23 °C), and the 
plasma or serum was collected and stored at −80 °C until analysis. 
 
2.1.4 Intervention treatment 
Symptomatic patients who suffered from chronic nausea and vomiting following 
RYGB were treated with subcutaneous injection of octreotide (50 mg) three times 
a day for 3 months. 
 
2.2 Blood measurement 
2.2.1 Assays 
Plasma glucose levels were determined with glucose hexokinase reagent (Roche, 
CA, USA). Serum-specific insulin levels were determined by ELISA (Mercodia, 
Sweden). Serum triglycerides, total, LDL and HDL cholesterol were assayed with 
commercial reagents (total cholesterol: Boehringer Mannheim, Sussex, UK; 
triglycerides: Roche Diagnostics, Herts, UK). All lipid assays were done by Dr 
David Wickens (Chemical Pathology, Whittington Hospital, London, UK). Insulin 
resistance was calculated using homeostatic model assessment (HOMA) = 
(glucose in mmol/L × insulin in mIU/L)/22.5 [299]. 
 
2.2.2 Adipokine ELISA 
Adipokine concentrations in serum including total adiponectin and leptin were 
determined by commercially available two-site ELISA (R&D Systems, UK). 
Standards and samples were pipetted into the 96 wells of a microplate pre-coated 
with a monoclonal antibody specific for the target adipokine. After incubation, any 
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adipokine present was bound to the antibody pre-coated onto the bottom of the 
well. The unbound substances were then washed away, followed by the addition 
of a ‘detecting’ enzyme-linked monoclonal antibody specific for the target antigen, 
adipokine. After washing, to remove any unbound antibody-enzyme reagent, the 
substrate solution was added to the wells, and colour developed in proportion to 
the amount of adipokine bound in the initial step. The colour development was 
stopped at specified times as per the manufacturer’s instructions, and the 
intensity of the colour was measured using a microplate reader (Opsys MR, Dynex, 
UK) as absorbance at 450 nm, with correction at 540 nm. 
 
2.2.3 DPP-IV inhibitors 
Two different DPP-IV inhibitors were used. 
Aprotinin (non-specific protease inhibitor): aprotinin (500 kallikrein 
inhibitory units (KIU)/ml blood) from Sigma-Aldrich was used as DPP-IV 
inhibitor. 
P32/98 (50 mg) powder form (MW 260.4 g): a potent and selective inhibitor of 
DPP-IV (Enzo Life Sciences) was prepared by adding 5.84 ml of distilled water to 
the 50 g of inhibitor in order to obtain a final concentration of 330 µM of stock 
solution; 50 µL of the stock solution was added to 4 ml of blood. 
 
2.2.4 GLP-1 ELISA 
Two different commercially available ELISA kits were used to measure the 
bioactive form of GLP-1. 
GLP-1 ELISA kit (ALPCO immunoassays, ALPCO Diagnostic, USA): this ELISA 
was used to measure the active form of GLP-1 (7-36) in human EDTA-plasma by 
a sandwich technique with two selected GLP-1 (7-36)-specific antibodies. 
Standards, controls and samples were pipetted into the 96 wells of a microplate 
that was coated with streptavidin. Then, a mixture of biotinylated GLP-1 (7-36)-
specific antibody and a horseradish peroxidate (HRP)-conjugated GLP-1 (7-36)-
specific antibody was added to each well and left for overnight incubation, during 
 62 
which a sandwich immunocomplex was formed and adhered to the walls of the 
plate; unbound substances were then washed out. The substrate solution was 
then added to each of the wells for detection of immunocomplex, incubated in a 
timed reaction and then measured using a spectrophotometric microplate reader 
(Opsys MR, Dynex, UK) as absorbance at 450 nm, with correction at 620 nm. 
GLP-1 ELISA kit (Millipore, Billerica, MA, USA): this kit was used to measure 
both the active forms of GLP-1 (7-36) and GLP-1 (7-37) in plasma. Standards, 
controls and plasma samples were added to a GLP-1 monoclonal antibody-coated 
microwell plate that binds specifically to the N-terminal region of active GLP-1 
protein in the wells. The plate was incubated for at least 20 hours at 4 °C. The plate 
was then washed to remove unbound materials; an anti-GLP-1-alkaline 
phosphatase detection conjugate was added to the immobilized GLP-1 in the 
wells, and the plate was incubated for 2 hours at room temperature. After washing 
off unbound conjugate, methyl umbelliferyl phosphate (MUP) solution was added 
and left for at least 20 minutes to form a fluorescent product, umbelliferone, when 
in the presence of alkaline phosphatase-conjugated GLP-1. The MUP reaction was 
stopped by adding dipotassium phosphate reagent. The plate was read using a 
GENios Microplate Reader (TECAN Group Ltd, Switzerland) with an 
excitation/emission wavelength of 350/460 nm. 
 
2.3 Adipose tissue 
2.3.1 Adipose tissue sample collection 
Abdominal subcutaneous and intra-abdominal greater omentum adipose tissue 
(AT) (about 5 g each) were obtained during the intraoperative period, placed in 
serum-free medium (Cellgro, Mediatech, Manassas, USA) and then transferred 
quickly to the laboratory. 
 
2.3.2 GLP-1 recombinant preparation 
Recombinant human GLP-1 (9-36) amide was obtained from Polypeptide 
Laboratories and diluted in phosphate-buffered saline (PBS) with 0.1% bovine 
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serum albumin (BSA) to provide a 1 nM stock concentration. The peptide was then 
further diluted in PBS to obtain three different concentrations: 1, 0.5 and 0.1 nM. 
 
2.3.3 Adipose tissue organ culture with recombinant 
GLP-1 
Subcutaneous and omental AT (0.05 g) were dissected, and each was incubated in 
500 μl Cellgro serum-free media with 5% penicillin-streptomycin or three 
different concentrations of GLP-1 solution (0.1, 0.5 and 1 nM) for 4 or 16 hours 
(37 °C, 95% O2/5% CO2). Following incubation, the conditioned medium was 
collected and stored at −80 °C until assessment of leptin secretion. 
 
2.3.4 Collagenase digestion of adipose tissue 
Collagenase digestion of AT was used to obtain the adipocytes. AT was weighed, 
and 5 g each of subcutaneous (SC) and omental (OM) AT (SAT and OAT, 
respectively) were used for collagenase digestion. Both AT were minced in a boat 
using a scalpel and forceps. The minced tissue was placed in a 50-ml universal 
tube. To each tube, 1 ml of collagenase, 1.5 ml of BSA and 7.5 ml of Cellgro were 
added. The tubes were covered with parafilm and then incubated in a shaking 
water bath (~160/minute) at 37 °C for 45 minutes. The cell suspension was then 
filtered through a tissue sieve containing 8-mesh, transferred into a 15-ml Falcon 
tube and spun for 5 minutes (3000 rpm at 4 °C). The adipocytes were decanted 
and collected into an Eppendorf tube and taken immediately for RNA extraction. 
 
2.4 Adipocyte gene expression 
2.4.1 Cell RNA extraction 
Adipocytes were collected and homogenized using TRIzol reagent (Invitrogen, 
Life Technologies, UK). Then, chloroform was added and mixed thoroughly (0.2 
ml chloroform per 1 ml TRIzol). The mixture was centrifuged at 3200 rpm for 15 
minutes at 4 °C and was separated to form an upper colourless aqueous phase, 
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interphase, and lower red phenol-chloroform phase. The aqueous phase that 
contained the total RNA was then transferred to a new Eppendorf tube and mixed 
gently with an equal volume of 100% isopropanol. The mixture was incubated at 
−20 °C for 1.5 hours, then centrifuged (3200 rpm, 15 minutes, 4 °C). Subsequently, 
the RNA pellet that appeared on the bottom of the Eppendorf tube was washed 
twice in 75% ethanol (Sigma-Aldrich, UK) and finally re-suspended in nuclease-
free water (Invitrogen, Life Technologies, UK). 
The quality and concentration of the RNA extracted were assessed 
spectrophotometrically using a NanoDrop-1000 spectrophotometer (Thermo 
Scientific, USA). The concentration of RNA was recorded as the optical density 
(OD) at 260 nm, and the quality reported as the ratio of OD at 260 nm to that at 
280 nm. A 260/280 ratio >1.7 was acceptable quality for RNA. 
 
2.4.2 cDNA synthesis 
For synthesis of the first strand of cDNA, a reverse transcription reaction mixture 
was made with MultiScribe Reverse Transcriptase (1.25 units/μl), dNTP (ATP, 
CTP, GTP, UTP; 500 μL each), Oligo d(T)16 (2.5 μM), RNase inhibitor (0.4 units/μl), 
MgCl2 (5.5 mM) and reaction buffer (TaqMan Reverse Transcription Reagents, 
Roche, New Jersey, USA); 500 ng of total RNA was added to the mixture, and the 
mixture was then incubated in a thermal cycler (Genius, Techne, UK) at 42 °C for 
1 hour, at 72 °C for 15 minutes, and held at 4 °C. After that, the cDNA was stored 
at −20 °C. 
 
2.4.3 Real-time polymerase chain reaction (real-time 
PCR) 
Target gene expression was measured using TaqMan real-time PCR. The primers 
of β-actin (a housekeeping gene) and GLP-1 receptor used were obtained from 
Qiagen Company, UK. SYBR Green solution (12.5 μl), primer (2.5 μl), cDNA (10 μl) 
and nuclease-free water were mixed to form 25 μl of mixture. The reaction was 
carried out in triplicate in a 384-well plate using 10 μl total volume per well of the 
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mixture. The PCR reaction conditions were 50 °C for 2 minutes, 95 °C for 15 
minutes, followed by 40 cycles of 94 °C for 15 seconds, 56 °C for 30 seconds and 
76 °C for 30 seconds in an ABI Prism 7900HT sequence detection system (Applied 
Biosystems, UK). 
The cycle threshold (Ct) value was defined as the number of cycles required for 
the fluorescent signal to cross the threshold, and this was used to measure gene 
expression. Data were expressed as the Ct ratio of β-actin to the target gene. 
 
2.5 Statistical analysis 
Data were analysed using SPSS version 20 for Apple (Statistical Package for the 
Social Sciences, SPSS UK Ltd, Chertsey, UK). Normally distributed data are 
expressed as the mean (standard deviation), and non-normally distributed data 
are expressed as the median (interquartile range) in text and in tables. Non-
parametric data were tested using a Wilcoxon–Mann–Whitney U test. Significance 
was defined as p ≤ 0.05. 
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Chapter 3 
 
Elevated GLP-1 
mediates chronic 
nausea and 
vomiting 
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3.1 Introduction 
3.1.1 Nausea and vomiting (N&V) after bariatric surgery 
Bariatric surgery is, to date, the only intervention that results in significant and 
sustained weight loss for morbid obesity. Procedures such as RYGB, which 
combines gastric restriction with bypass of the stomach and proximal intestine, 
are more effective than other forms of metabolic surgery (GB and SG) [300]. 
However, a proportion of patients develop severe, sustained and debilitating N&V 
symptoms of unknown cause after RYGB, as well as with other procedures such 
as SG, which starts late after the surgery (at least 1 year), persists for more than 3 
months and is not related to mechanical obstruction [301, 302]. The mechanism 
underlying this phenomenon is unknown, but the symptoms are similar to those 
experienced by patients with gastroparesis characterized by delayed gastric 
emptying of solids without evidence of mechanical obstruction. Symptomatic 
improvement occurs in these patients with gastric electrical stimulation which 
has been shown to enhance vagal autonomic function, decrease gastric sensitivity 
to volume distension and activate central control mechanisms for N&V through 
thalamic pathways [303]. 
 
3.1.2 GLP-1 is associated with nausea 
A recognized side effect of GLP-1 analogues used to treat diabetes is nausea which 
occurs in up to 50% of patients [304]. Studies in rats suggest that the nausea-
inducing effects of peripheral exendin-4, a GLP-1 receptor agonist, are mediated 
by a vagal-independent pathway that appears to involve BBB penetration and 
subsequent GLP-1R activation in the CNS, most likely in the NTS [150]. 
Postprandial GLP-1 plasma levels are significantly increased following RYGB, and 
remain elevated for at least a year [305]. Whether the increase in GLP-1 levels 
after surgery could also be a contributing factor to the persistent N&V 
experienced by some patients has not been reported. 
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3.1.3 Leptin and nausea 
There is also data suggesting a relationship between leptin and symptoms of 
severe, but not mild to moderate, nausea in women during pregnancy [306, 307]. 
Furthermore, the most common side effect of treatment with metreleptin is 
nausea [308]. Thus, whether leptin may provoke N&V in a subset of women 
following RYGB has not been investigated. 
Thus, the hypothesis of this study was that elevated GLP-1 levels might be 
associated with persistent N&V experienced by a subset of patients following 
RYGB, and that administration of GLP-1 inhibitor may ameliorate these 
symptoms. Secondly, GLP-1 directly alters leptin secretion by adipocytes, and, 
together, GLP-1 and leptin augment the symptoms of N&V. 
The aims of this study were to investigate whether increased GLP-1 and leptin 
levels after surgery could be a contributing factor to persistent N&V, by 
comparing post-absorptive and postprandial levels of GLP-1 and leptin between 
asymptomatic subjects and patients with persistent N&V following RYGB, and 
between normal-weight, overweight, obese and morbidly obese subjects not 
scheduled for surgery. The second aim was to determine the possibility of 
crosstalk between gut peptides and adipokines, by investigating the effect of GLP-
1 on leptin secretion in vitro. 
 
3.2 Methods 
3.2.1 In vivo study 
Study population 
Forty-two non-diabetic female subjects stratified into five groups participated in 
this study: obese subjects with persistent and prolonged N&V after RYGB (Group 
1: n = 10), asymptomatic postoperative obese subjects (Group 2: n = 10), morbidly 
obese subjects (Group 3: n = 7), overweight/obese subjects (Group 4: n = 6) and 
normal-weight healthy subjects (Group 5: n = 9). Subjects in Group 1 had upper 
gastrointestinal tract endoscopy and imaging to exclude an obstructive cause for 
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their symptoms. Weight, height, BMI, BP and pulse were recorded. Exclusion 
criteria were as mentioned in section 2.1.1. 
 
Meal challenge test 
Day of visit: subjects attended the research clinic at the Whittington Hospital 
between 8:30 and 10 AM after an overnight fast. The postoperative patients were 
studied 18.8 ± 3.0 months after surgery. A cannula was inserted into a forearm 
vein, and fasting blood samples were collected for measurement of plasma 
glucose, lipids, insulin, leptin, adiponectin and GLP-1. Subjects consumed a 182.7-
kcal solid meal (10.3 g of fat, 18.9 g of carbohydrate and 3.6 g of protein), and 
additional blood samples for GLP-1, glucose and insulin were collected 45, 120 
and 180 minutes after the meal; 250 l of aprotinin was added immediately to 
each blood sample taken for GLP-1 to prevent degradation by DPP-IV enzyme. 
Blood samples were centrifuged at 3000 rpm for 15 minutes at 23 C and stored 
at −80 C until analysis. This meal size was used as subjects with postoperative 
N&V were unable to tolerate a larger meal. 
 
Treatment intervention 
One symptomatic patient received subcutaneous injections of octreotide three 
times a day for 3 months, after which the meal challenge test was repeated (as 
above), and blood was taken in the fasted state for measurement of GLP-1 level. 
 
Assay 
Glucose, total cholesterol, LDL, HDL and triglycerides were assayed at the 
Whittington Hospital as mentioned in section 2.2.1. Insulin, leptin and 
adiponectin were determined by ELISA (sections 2.2.1 and 2.2.2). GLP-1 was 
measured using ELISA (ALPCO immunoassays, ALPCO Diagnostic, USA), as 
detailed in section 2.2.4. 
HOMA was calculated as mentioned earlier in section 2.2.1. 
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3.2.2 In vitro study 
Subjects 
Abdominal SAT and OAT samples were obtained from morbidly obese non-
diabetic patients undergoing bariatric surgery (n = 6), for use in organ cultures. 
 
Tissue culture 
SAT and OAT (0.05 g) were incubated in 500 µl of three different concentrations 
of human GLP-1 (0.1, 0.5 and 1.0 nM) as well as Cellgro (control 0) for 4 or 16 
hours. Culture media were collected, and leptin levels were determined by ELISA 
(section 2.2.2). 
 
Gene expression in cells 
Collagenase digest for SAT and OAT was done to obtain the adipocyte fraction; the 
method is described in section 2.3.4. 
RNA extraction from SC and OM adipocytes was carried out as described in section 
2.4.1 and followed by cDNA synthesis (section 2.4.2). 
GLP-1 receptor expression was quantified using real-time PCR; the method is 
described in section 2.4.3. 
 
3.3 Results 
3.3.1 Patients’ characteristics 
Patients’ characteristics are shown in Table 3.1. All subjects were female, non-
diabetic, normotensive and normolipidaemic. Appendix 1 shows the medications 
that were used by participants in the different groups. The groups were matched 
for age, and the two postoperative groups were matched for BMI and 
postoperative duration (18.8 ± 3.0 months). BMI on the day of study varied 
according to the group. The mean BMI of morbidly obese patients and normal-
weight subjects were 46.3 and 21.3 kg/m2, respectively. The BMI of the 
postoperative and the obese/overweight patients was not significantly different. 
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 Group 1 
N&V 
(n = 10) 
Group 2 
No N&V 
(n = 10) 
Group 3 
MO 
(n = 7) 
Group 4 
OW 
(n = 6) 
Group 5 
NW 
(n = 9) 
Age (years) 41.4 ± 3.4 38 ± 3.1 39.3 ± 4.3 45.5 ± 3.9 34.7 ± 4.6 
BMI (kg/m2) 30.6 ± 2.3 31.2 ± 2.0 46.3 ± 1.7 31.8 ± 1.9 21.3 ± 0.7 
SBP (mm Hg) 119 ± 3 109 ± 3 127 ± 7 121 ± 12 121.3 ± 1 
DBP (mm Hg) 73 ± 5 72 ± 3 81 ± 4 79 ± 2 76.6 ± 12 
Basal glucose 
(mmol/l) 
5.0 ± 2.4 4.5 ± 0.5 5.07 ± 0.9 5.2 ± 0.7 4.7 ± 0.5 
Basal insulin 
(mIU/l) 
5.0 ± 2.4 4.5 ± 1.5 10.2 ± 7.5 9.4 ± 4.1 4.1 ± 2 
HOMA-IR 1.2 ± 0.6 0.9 ± 0.3 2.4 ± 2.2† 2.1 ± 0.8† 0.8 ± 0.4 
Total 
cholesterol 
(mmol/l) 
3.5 ± 0.35 4.1 ± 0.12 4.0 ± 0.43 4.4 ± 0.26 4.9 ± 0.38 
HDL 
cholesterol 
(mmol/l) 
1.2 ± 0.12 1.4 ± 0.12 0.99 ± 0.07 1.3 ± 0.14 1.9 ± 0.29* 
LDL 
cholesterol 
(mmol/l) 
1.8 ± 0.29 2.4 ± 0.25 2.5 ± 0.41 2.7 ± 0.23 2.6 ± 0.29 
Triglycerides 
(mmol/l) 
1.1 ± 0.23 0.85 ± 0.05 1.1 ± 0.18 0.81 ± 0.24 0.81 ± 0.13 
 
Table 3.1 Patients' characteristics 
SBP: systolic blood pressure, DBP: diastolic blood pressure, HOMA-IR: homeostatic 
model assessment – insulin resistance, HDL: high-density lipoprotein, LDL: low-density 
lipoprotein, N&V: nausea and vomiting, MO: morbidly obese, OW: obese and 
overweight, NW: normal weight. † denotes p < 0.05 compared to the post-surgery and 
normal-weight groups; * denotes p < 0.05 comparing the normal-weight group to all 
other groups. 
 72 
3.3.2 BMI in postoperative groups 
The patients with N&V and those without symptoms were followed up after 
surgery over a period of 14–18 months to find out if those with symptoms lost 
more weight. The figure below shows that weight loss following RYGB surgery 
was not significantly different in subjects with and without N&V for up to 18 
months (Figure 3.1). 
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Figure 3.1 Weight loss following Roux-en-Y gastric bypass in subjects with 
and without persistent nausea and vomiting symptoms 
BMI in patients with and without persistent N&V symptoms was recorded for 15 
months following RYGB (n = 10 per group). There were no significant differences 
in the change in BMI over time between the two groups. Data are shown as mean 
and standard deviation and comparisons carried out by t-test. N&V: nausea and 
vomiting, BMI: body mass index, RYGB: Roux-en-Y gastric bypass. 
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3.3.3 Post-absorptive and postprandial circulating GLP-1 
levels 
Fasting plasma GLP-1 levels were significantly higher in the subjects with 
persistent N&V post-RYGB surgery compared to all other groups (p = 0.007), as 
shown in Figure 3.2. This difference was significant (p = 0.035) despite similar 
BMI (p = 0.86) in the two postoperative groups. Postprandial GLP-1 levels did not 
increase significantly at 45, 120 and 180 minutes following the meal challenge 
compared to fasting levels in either operative or non-operative groups (Table 3.2). 
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Figure 3.2 Changes in fasting levels of GLP-1 
Fasting plasma GLP-1 levels. In subjects with persistent N&V, fasting GLP-1 levels 
were elevated (p = 0.035) compared to subjects without N&V, morbidly obese 
subjects, obese and overweight subjects and lean subjects. Data are shown as 
median and interquartile ranges and comparisons made by Mann–Whitney U test. 
Groups: postoperative nausea and vomiting (N&V) n = 10; postoperative non-
N&V n = 10; morbidly obese (MO) n = 7; obese and overweight (OW) n = 6; normal 
weight (NW) n = 9. 
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Group 1 
N&V 
Group 2 
No N&V 
Group 3 
MO 
Group 4 
OW 
Group 5 
NW 
Fasting 
GLP-1 (PM) 
14.5 
(10–17.5) 
8.3 
(7.0–9.5) 
4.0 
(1.5–5.2) 
6.0 
(3.0–7.1) 
8.0 
(7.0–8.5) 
45 min PP 
GLP-1 (PM) 
16.5 
(11.9–94.8) 
7.6 
(4.9–8.4) 
4.9 
(3.7–10.0) 
7.3 
(4.4–10.5) 
7.4 
(4.5–10.9) 
120 min PP 
GLP-1 (PM) 
13.1 
(10.1–90.2) 
8.1 
(4.7–8.0) 
4.4 
(3.5–11.0) 
8.1 
(4.1–10.2) 
6.2 
(4.3–8.3) 
180 min PP 
GLP-1 (PM) 
14.4 
(9.5–89.6) 
5.6 
(4.2–7.8) 
4.0 
(3.1–10.0) 
7.6 
(3.2–10.6) 
6.0 
(4.6–7.7) 
 
Table 3.2 Fasting and postprandial GLP-1 levels in the five different groups 
Data are expressed as median and interquartile range. N&V = postoperative nausea and 
vomiting, No N&V = postoperative without nausea and vomiting, MO = morbidly obese, 
OW = obese and overweight, NW = normal weight. 
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3.3.4 Fasting systemic adipokine levels and BMI 
Fasting systemic leptin and BMI are shown in the graph below (Figure 3.3). As 
expected, morbidly obese subjects had high systemic leptin levels. Subjects with 
postoperative N&V had significantly lower plasma leptin (p = 0.04) compared to 
those without N&V, similar to the levels in normal-weight subjects. As expected, 
adiponectin levels were lower in the morbidly obese and obese/overweight 
groups and highest in the normal-weight group. However, levels were lower in 
subjects with postoperative N&V compared to asymptomatic subjects, but this did 
not reach significance (p = 0.30) (Figure 3.4). 
  
 78 
 
 
Figure 3.3 BMI and fasting systemic leptin 
Although BMI (A) were similar between N&V and non-N&V groups, plasma leptin 
levels (B) were significantly lower in N&V groups compared to non-N&V groups 
(p = 0.04) and to morbidly obese and obese/overweight groups (p < 0.05). Levels 
were comparable between the N&V group and the lean group (p = 0.9). Data in 
(A) are shown as mean (SD) and in (B) as median (interquartile range). Groups: 
postoperative nausea and vomiting (N&V) n = 10; postoperative non-N&V n = 10; 
morbidly obese (MO) n = 7; obese and overweight (OW) n = 6; normal weight 
(NW) n = 9.  
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Figure 3.4 Fasting plasma adiponectin levels 
Plasma adiponectin was not significantly different between N&V and non-N&V 
groups (p = 0.2). Circulating adiponectin levels were significantly lower in the 
morbidly obese group compared to no N&V and normal-weight groups (p < 0.05), 
whereas the levels were comparable between the normal-weight and 
postoperative N&V and no N&V groups (p > 0.05). Data are shown as median 
(interquartile range); comparisons were made by Mann–Whitney U test. Groups: 
postoperative nausea and vomiting (N&V) n = 10; postoperative non-N&V n = 10; 
morbidly obese (MO) n = 7; obese and overweight (OW) n = 6; normal weight 
(NW) n = 9. 
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3.3.5 Glucose and insulin response 
There was no significant difference in the glucose and insulin response to the meal 
challenge in subjects with and without postoperative N&V (Table 3.3, Figures 3.5 
and 3.6). 
  
 81 
 
Table 3.3 Fasting and postprandial (45, 120 and 180 minutes) glucose and 
insulin plasma levels 
Data are expressed as median and interquartile ranges. N&V: nausea and vomiting, PP: 
postprandial, min: minute, h: hour. 
  
 Group 1 
N & V 
Group 2 
No N & V 
 
           P value 
 
 
Fasting glucose 
(mM) 
 
 
4.4 (4.2- 4.9) 
 
4.3 (4.0-5.0) 
 
0.5 
45 min PP glucose 
(mM) 
 
4.9 (4.8-6.2) 5.4 (4.4-7.0) 0.9 
2 h PP glucose 
(mM) 
 
4.3 (3.9-4.8) 4.2 (3.5-4.8) 0.8 
3 h PP glucose 
(mM) 
 
4.3 (4.1-4.8) 4.3 (4.0-4.7) 0.7 
Fasting insulin 
(mIU/ml) 
 
5.5 (2.9-6.4) 4.7 (3.5-5.5) 0.6 
45 min PP insulin 
(mIU/ml) 
13.1 (5.1-32.8) 19.2 (11.3-32.2) 0.4 
2 h PP insulin 
(mIU/ml) 
 
4.2 (2.8-4.8) 5.1 (4-10.4) 0.2 
3 h PP insulin 
(mIU/ml) 
 
3.3 (2.8-5.4) 3.8 (2.8-4.7) 0.9 
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Figure 3.5 Glucose response to a meal challenge in subjects with (A) and 
without (B) nausea and vomiting after Roux-en-Y gastric bypass surgery 
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Following a 182.7-kcal meal challenge, the glucose responses were similar in 
subjects with and without N&V symptoms (A and B) after Roux-en-Y gastric 
bypass surgery. Data are shown as median and interquartile ranges and 
comparisons made with a Mann–Whitney U test. 
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Figure 3.6 Insulin response to a meal challenge in subjects with (A) and 
without (B) nausea and vomiting after Roux-en-Y gastric bypass surgery 
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Following a 182.7-kcal meal challenge, the insulin responses were similar in 
subjects with (A) and without N&V symptoms (B) after Roux-en-Y gastric bypass 
surgery. Data are shown as median and interquartile ranges and comparisons 
made with a Mann–Whitney U test. 
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3.3.6 Treatment intervention 
Octreotide injection (50 mg three times a day) was given to one patient with 
persistent N&V. The patient reported amelioration in N&V symptoms with the 
onset of the treatment, and her basal plasma GLP-1 levels decreased (basal GLP-1 
pre-treatment versus post-treatment: 6.35 versus 5.24 pM). 
 
3.3.7 Leptin secretion in response to GLP-1 (in vitro) 
Minimal leptin secretion was detected from either SAT or OAT after 4 hours’ 
incubation (Figure 3.7 A). However, there was significant suppression of leptin 
secretion in SAT at all concentrations of GLP-1 used (0.1, 0.5 and 1 nM) after 16 
hours’ incubation (Figure 3.7 B). Leptin secretion from OAT was very low, and 
significantly lower than that from SAT, so that the effect of GLP-1 on leptin 
secretion could not be recognized. 
 
3.3.8 GLP-1 receptor expression in adipocytes 
Both SC and OM adipocytes showed the presence of GLP-1 receptors. There was 
no difference in mRNA expression of GLP-1 receptors between SC and OM 
adipocytes (Figure 3.8). 
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Figure 3.8 GLP-1 receptor mRNA expression in subcutaneous (SC) and 
omental (OM) adipocytes 
Expression of GLP-1 receptor in SC (control) and OM adipose tissues was calculated by 
the 2−ΔΔCT method (n = 3). A paired-sample t-test indicated no significant difference in the 
level of expression between the two depots. Data are presented as mean and standard 
deviation. SC = subcutaneous, OM = omental. 
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3.4 Discussion 
3.4.1 Elevated basal GLP-1 is associated with chronic 
symptoms of nausea and vomiting 
N&V is a common side effect experienced by the majority of patients undergoing 
RYGB, but symptoms usually disappear shortly after the operation [309]. 
However, approximately 1–5% of patients present with difficult-to-control 
persistent N&V despite the absence of mechanical abnormalities [301]. In this 
study, it was found that symptomatic patients have significantly higher basal, but 
not postprandial, GLP-1 levels, suggesting that non-mechanical chronic N&V 
symptoms after RYGB surgery may be due, at least in part, to chronically elevated 
GLP-1 levels. Increased GLP-1 concentrations may therefore also explain similar 
symptoms seen after other bariatric procedures such as SG [310]. Postprandial 
GLP-1 responses were not apparent in all groups. This might be due to the small 
amount of caloric intake that was inadequate to stimulate postprandial GLP-1 
secretion. However, this still does not detract from the result that GLP-1 was 
elevated, although only evidence for elevated fasting levels mediating chronic 
nausea/vomiting is provided by this study. 
A significant number of diabetic patients treated with exendin-4 also experience 
N&V [150], providing further support for the role of elevated GLP-1 levels in the 
generation of symptoms. 
Exendin-4 induces nausea by penetrating the BBB and subsequently activating 
GLP-1R in the medial NTS [150, 304]. Whether GLP-1 induces N&V by direct 
actions on the NTS or indirectly through the vagal afferent pathway is not known. 
However, endogenous GLP-1 has a very short half-life and is rapidly degraded by 
DPP-IV enzyme, which makes it unlikely to cross the BBB. 
Despite higher basal GLP-1 levels in symptomatic patients compared to those 
without symptoms postoperatively, weight loss, insulin sensitivity and 
adiponectin levels were not significantly different in the two groups. Thus, the 
beneficial effects of RYGB on improving insulin sensitivity and weight loss were 
not affected by elevated basal GLP-1 levels and the symptoms of N&V. 
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3.4.2 Leptin secretion in vivo and in vitro 
Contrary to data for the persistent N&V that accompanies pregnancy [306, 307], 
systemic leptin levels were lower in the symptomatic compared to asymptomatic 
subjects, despite similar postoperative BMI. The in vitro study showed that 
chronic (16 h) but not acute (4 h) exposure to GLP-1 inhibited leptin secretion 
from human SAT but not OAT. Leptin secretion from OAT was significantly lower, 
and the effect of GLP-1 on leptin secretion was unclear. GLP-1 has been shown to 
inhibit visfatin, and exendin-4 to stimulate adiponectin secretion from 3T3-L1 
adipocytes [153, 154]. Acute administration of synthetic human GLP-1 to obese 
patients with and without type 2 diabetes mellitus reduces circulating IL-6 only 
in those with type 2 diabetes mellitus, without affecting levels of leptin, 
adiponectin or obestatin [311]. Chronic central infusion of exendin-4 reduces 
circulating leptin levels in lean but not obese rats [155]. Therefore, it appears that 
only chronic, but not acute, exposure to elevated levels of GLP-1, either in vivo or 
in vitro, leads to inhibition of leptin. 
It has been suggested that leptin modulates peripheral GLP-1 secretion from L 
cells [118], which confirms that it plays a part in regulating peripheral GLP-1 
production. As leptin stimulates GLP-1 secretion in a negative feedback 
mechanism, GLP-1 may directly inhibit leptin secretion. 
Inhibition of leptin secretion by GLP-1 was observed in SAT, the major depot 
contributing to its systemic levels. That this is a direct effect on secretion rather 
than a reflection of differences in fat mass in patients with and without N&V is 
substantiated by the fact that the groups with and without N&V had similar BMI, 
insulin sensitivity and adiponectin levels, as well as similar lipid profiles. 
 
3.4.3 Treatment intervention 
The non-mechanical N&V symptoms experienced by some patients were 
associated with high baseline levels of GLP-1. We hypothesized that the symptoms 
may be ameliorated by treatment with GLP-1 inhibitors, but potential detrimental 
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effects on weight maintenance and insulin sensitivity need to be considered. One 
of the patients in this study was treated with octreotide, a somatostatin analogue 
that inhibits GLP-1 secretion [312], and reported an improvement in N&V 
symptoms, with a concomitant reduction in basal and postprandial GLP-1 levels. 
However, octreotide also suppresses other gut hormones, such as PYY, which also 
decrease appetite and increase weight loss and are increased after RYGB surgery 
[312]. Therefore, specific GLP-1 antagonists, such as exendin 9-39, might be more 
beneficial for improving N&V symptoms, without interfering with secretion of 
other gut peptides that may potentially affect weight loss and insulin sensitivity 
adversely. 
 
3.4.4 GLP-1 receptor gene expression in adipocyte s 
It was observed in the in vitro study that, unlike SAT, leptin secretion from OAT in 
response to control and GLP-1 conditions was significantly lower. This could not 
be explained by low expression of GLP-1 receptors in the OM depot, as it was 
found that GLP-1 R mRNA was expressed equally in both SC and OM adipocytes 
(the secretory site of leptin). Vendrell et al. previously reported that lean and 
obese human adipocytes of the SC, compared to OM, express more GLP-1R [126]. 
Perhaps in morbid obesity this depot-specific difference in GLP-1R is lost. 
This study showed a direct effect of GLP-1 on the secretion of an adipokine, leptin, 
by human AT. Chronic elevation of the gut peptide has an inhibitory effect on both 
systemic leptin levels and its secretion from AT. Previous reports of decreased 
leptin levels early after RYGB, prior to significant reduction in BMI [19], might be 
explained by GLP-1-mediated inhibition of leptin. The findings in this study 
suggest that persistent N&V after RYGB surgery may be mediated by elevated 
fasting GLP-1 levels. Further studies are required to determine if treatment with 
specific GLP-1 antagonists ameliorates N&V symptoms without detrimental 
effects. 
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3.4.5 Study limitations 
The GLP-1 ELISA kit used in this study did not measure all active forms of GLP-1. 
Other kits that detect all active forms of GLP-1 might have given more 
comprehensive results and also shown conclusively if postprandial GLP-1 levels 
in N&V patients are higher than those in non-N&V patients. 
Only one symptomatic patient was treated with a GLP-1 antagonist; therefore, 
increasing the number of patients treated with specific GLP-1 antagonists is 
required to be able to reach any conclusions on the effect of reducing GLP-1 in 
order to manage patients with chronic N&V following several forms of bariatric 
surgery. 
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Chapter 4 
 
Differential effect of 
primary obesity surgery 
endoluminal (POSE) 
compared to Roux-en-Y 
gastric bypass (RYGB) 
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4.1 Introduction 
4.1.1 Primary obesity surgery endoluminal (POSE) 
The long-term challenges facing metabolic surgery are to help identify which 
procedure is most suited to individual patients and to develop more efficient and 
cost-effective, and less invasive procedures, while investigating other therapeutic 
strategies that provide similar weight loss and metabolic benefits. Bariatric 
surgery, in keeping with other invasive procedures, has a morbidity rate of 2–17% 
and a mortality rate of 0.1–0.3%, creating a need to identify less invasive and safer 
alternatives [313]. 
POSE is a new form of weight-loss surgery which is performed endoscopically 
inside the stomach (Figure 4.1). The procedure has been successfully performed 
in a small number of pioneering centres around the world, mainly in the United 
States and recently in Europe [314]. This procedure is generally offered to 
patients seeking weight-loss surgery who have a BMI between 30 and 40. POSE 
may also be a treatment option for morbidly obese people who are not suitable 
for more invasive weight-loss procedures [314]. 
The POSE procedure is performed under general anaesthesia and takes 60–90 
minutes [315]. The technique consists of using a multifunctional endoscopic 
platform known as an incisionless operating platform (IOP) that is introduced into 
the mouth and provides access to the stomach [316]. A g-CathTM EZ Delivery 
catheter with suture anchors (USGI, PA, USA) is then used to create a series of 
plications or gastric folds in the fundus (seven to nine plications) and in the 
antrum body on the front face (three plications) [314](Figure 4.2). 
Normally, ingested food stimulates gastric stretch receptors, resulting in 
relaxation of the fundus and an increase in stomach volume to accommodate the 
meal without causing pressure. Anchored plications may partially affect the 
function of the fundus and restrict its ability to relax, by accelerating the activation 
of gastric stretch receptors in response to food, thereby causing an early feeling 
of fullness. Antral plications may further prolong satiety and decrease hunger by 
slowing down gastric emptying [317, 318]. 
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Compared to open and laparoscopic bariatric surgery, POSE is considered a safer 
procedure and is effective in achieving up to 45% EWL with no scarring or pain, 
and no major complications such as bleeding, leakage, wound infection or 
anastomotic stricture [314, 315]. However, it is not known whether the POSE 
procedure affects gastrointestinal hormone levels and improves metabolic 
parameters as seen after RYGB, or whether it has any effect on specifically 
improving insulin sensitivity. 
 
Therefore, the hypotheses of this study were: 
 The POSE procedure produces weight loss comparable to RYGB and also 
induces beneficial metabolic changes. 
 
To explore these hypotheses, the aims of this study were to compare changes in: 
 weight prior to and at 1 week, 2 months and 6 months after POSE and 
RYGB, and 
 systemic glucose, insulin, lipids, GLP-1, leptin and adiponectin levels prior 
to and at 1 week, 2 months and 6 months after POSE and RYGB. 
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Figure 4.1 Primary obesity surgery endoluminal (POSE) (adapted from 
Southampton Hospital) 
 
 
 
 
Figure 4.2 g-CathTM EZ suture anchor holding plicated gastric tissue [249] 
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4.2 Methods 
Study population 
Sixteen patients awaiting weight-reducing surgery, either POSE or RYGB, were 
recruited. Group 1: six POSE patients; Group 2: ten RYGB patients matched for age 
and gender with the POSE patients. 
Subjects were asked to visit the outpatients’ clinic at the Whittington Hospital on 
four separate occasions: 1) 10 days prior to surgery, and then at 2) 1 week, 3) 2 
months and 4) 6 months after surgery. Subjects attended the outpatients’ clinic in 
the morning after an overnight fast. 
Height (m), weight (kg), BMI (kg/m2), blood pressure (mm Hg) and pulse (beats 
per minute) were recorded at each visit. 
A cannula was inserted into the forearm vein, and fasting blood samples were 
collected for measurement of plasma glucose, lipids, insulin, leptin, adiponectin 
and GLP-1. 
Subjects consumed a standard 388.6-kcal liquid mixed meal (17.4 g of fat, 40 g of 
carbohydrate and 18 g of protein), and additional blood samples for GLP-1, 
glucose and insulin were collected 30, 120 and 180 minutes after the meal. 
Blood samples for GLP-1 were taken and immediately mixed with 50 µL of DPP-
IV inhibitor. 
Blood samples were centrifuged at 3000 rpm for 15 minutes at 23 C and stored 
at –80 C until analysis. 
 
Assay 
Glucose, total cholesterol, LDL, HDL and triglycerides were assayed as mentioned 
in section 2.2.1. Insulin, leptin and adiponectin were determined by ELISA 
(sections 2.2.1 and 2.2.2). GLP-1 was measured using ELISA (Millipore, Billerica, 
MA, USA), as detailed in section 2.2.4. 
HOMA was calculated as mentioned earlier in section 2.2.1. 
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4.3 Results 
4.3.1 Patients’ characteristics 
Patients’ characteristics are shown in Table 4.1. All patients were female. The 
POSE group included two type 2 diabetes mellitus patients (one was taking 
metformin 1 g three times a day and gliclazide 30 mg twice a day, and the other 
one was on dietary control therapy. The RYGB group included two type 2 diabetes 
mellitus patients (one on metformin 3 g a day and pioglitazone 50 mg a day, the 
other patient on metformin 1 g three times a day). The anti-diabetic medications 
were reduced gradually post-RYGB until they were stopped at 6 months; however, 
the diabetic patients continued to require anti-diabetic medications post-POSE. 
The groups were matched for age; mean age (±SD) for POSE versus RYGB groups 
was 50.0 (± 14.8) versus 50.9 (± 6.9) years, p = NS. Prior to surgery, the weight 
and BMI of the POSE patients was lower but did not reach statistical significance 
(POSE vs RYGB, weight (±SD) kg, BMI (±SD) kg/m2: POSE 111.66 (± 11.05) kg and 
41.32 (± 2.84) kg/m2, RYGB 126.37 (± 32.03) kg and 47.41 (± 10.15) kg/m2; p = 
0.3). Systolic and diastolic blood pressure and pulse were comparable in both 
groups (p = NS). However, compared to POSE patients, RYGB patients were 
hyperinsulinaemic (fasting insulin, median and interquartile range 4.96 (2.36–
6.48) versus 9.8 (8.37–13.9) mIU/ml, respectively). 
Table 4.2 shows the fasting levels of adipokines and GLP-1 prior to surgery. 
Leptin, adiponectin and GLP-1 were comparable in both groups (p = NS). 
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Variables POSE (n = 6) RYGB (n = 10) p† 
Age (years) 50.0 (± 14.8) 50.9 (± 6.9) 0.9 
BMI (kg/m2) 41.3 (± 2.8) 47.4 (± 10.1) 0.2 
Weight (kg) 111.6 (± 11.0) 126.3 (± 32.1) 0.3 
Pulse (units) 84.0 (± 14.8) 85.0 (± 11.0) 0.9 
SBP (mm Hg) 137.5 (± 14.8) 129 (± 11.7) 0.1 
DBP (mm Hg) 84.5 (± 8.7) 83.9 (± 8.0) 0.9 
Total cholesterol 
(mmol/L) 4.1 (± 0.37) 4.3 (± 1.13) 0.6 
Triglycerides 
(mmol/L) 0.92 (± 0.68) 1.36 (± 0.8) 0.19 
LDL cholesterol 
(mmol/L) 2.03 (± 0.35) 2.4 (± 1.02) 0.4 
HDL cholesterol 
(mmol/L) 1.6 (±0.8) 1.2 (± 0.3) 0.05 
Glucose (mmol/L) 8.98 (± 4.61) 5.81 (± 1.29) 0.06 
Insulin (mIU/L) 4.96 (2.36–6.48) 9.8 (8.37–13.9) 0.005 
HOMA 1.44 (0.47–2.7) 2.51 (1.88–3.81) 0.08 
 
Table 4.1 Patients' characteristics 
SBP: systolic blood pressure, DBP: diastolic blood pressure, HOMA-IR: 
homeostatic model assessment – insulin resistance, HDL: high-density 
lipoprotein, LDL: low-density lipoprotein, p†: p value, POSE: primary obesity 
surgery endoluminal, RYGB: Roux-en-Y gastric bypass. Data are shown as mean (± 
SD) or median (interquartile ranges). 
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Variables POSE (n = 6) RYGB (n = 10) p† 
Leptin (ng/ml) 65.0 (49.9–114.2) 78.4 (50.0–120.0) 0.7 
Adiponectin 
(g/ml) 7.2 (5.4–10.5) 6.3 (3.9–8.7) 0.4 
GLP-1 (pM) 5.4 (5.3–5.6) 5.0 (4.2–5.9) 0.5 
 
Table 4.2 Fasting levels of adipokines and GLP-1 prior to surgery 
RYGB = Roux-en-Y gastric bypass, GLP-1: glucagon-like peptide 1, p†: p value. Data 
are shown as median (interquartile range). 
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4.3.2 Weight-loss outcome 
The changes in weight and BMI before and after (1 week, 2 months and 6 months) 
the procedures are shown in Figures 4.3 and 4.4. Both groups had lost weight 
significantly at 2 months. However, RYGB patients continued to lose weight at 6 
months, compared to POSE patients. At 6 months, the total body weight loss 
(TBWL) in the POSE group (14.16 ± 9.2 kg) was less than that in the RYGB group 
(36.1 ± 10.47 kg). In addition, the percentage of excess weight loss (%EWL) was 
greater in the RYGB group (53.47 ± 14.06%) than in the POSE group (26.6 ± 
16.6%). 
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Figure 4.3 Changes in weight before and 1 week, 2 months and 6 months 
after POSE (A) and RYGB (B) 
Weight was recorded for both POSE and RYGB patients before and 1 week, 2 
months and 6 months after surgery. Both groups had lost significant weight at 1 
week and 2 months after the procedures; however, more weight reduction was 
seen at 6 months in RYGB patients than in POSE patients, some of whom regained 
weight. POSE: primary obesity surgery endoluminal, RYGB: Roux-en-Y gastric 
bypass, WT0: 1 week before surgery, WT1W: 1 week after surgery, WT2M: 2 
months after surgery, WT6M: 6 months after surgery. 
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Figure 4.4 Changes in BMI before and 1 week, 2 months and 6 months after 
POSE (A) and RYGB (B) 
BMI were recorded for both POSE and RYGB patients before and 1 week, 2 months 
and 6 months after surgery. Both groups had significantly lower BMI at 1 week 
and 2 months after the procedures; however, a greater reduction in BMI was seen 
at 6 months in RYGB patients than in POSE patients, some of whom regained 
weight. POSE: primary obesity surgery endoluminal, RYGB: Roux-en-Y gastric 
bypass, BMI: body mass index, WT0: 1 week before surgery, WT1W: 1 week after 
surgery, WT2M: 2 months after surgery, WT6M: 6 months after surgery. 
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4.3.3 Changes in blood pressure, heart rate and lipid 
profile 
There were no significant differences in SBP at 1 week, 2 months and 6 months 
after POSE and RYGB compared to the baseline (p > 0.05). There were no 
significant differences in DBP at 1 week, 2 months and 6 months (82.3 ± 7.09, 
81.83 ± 11 and 83.5 ± 6 mm Hg, respectively) after POSE compared to the baseline 
(84.5 ± 8.6 mm Hg). Moreover, there were no significant differences in DBP at 1 
week, 2 months and 6 months (81 ± 9, 87.7 ± 9 and 85 ± 22 mm Hg, respectively) 
after RYGB compared to the baseline (83.9 ± 8 mm Hg). 
There were no significant differences in heart rate at 1 week, 2 months and 6 
months after surgery in either POSE or RYGB groups (POSE 91 ± 20, 79 ± 18 and 
82 ± 11 beats; RYGB 94 ± 15, 81 ± 11 and 83 ± 10 beats, respectively) compared 
to the preoperative baseline (84.3 ± 14.8 and 85.7 ± 11.7 beats, respectively). 
Table 4.3 shows the circulating lipid levels before and after POSE and RYGB 
procedures. In POSE and RYGB patients, total cholesterol decreased significantly 
(p < 0.05) at 1 week (3.7 ± 0.5 and 3.8 ± 0.7 mmol/L, respectively) compared to 
preoperative levels (4.1 ± 0.3 and 4.3 ± 1.1 mmol/L, respectively). However, at 2 
and 6 months, the concentrations were comparable to the baseline in both groups. 
HDL showed a significant increase (p < 0.05) in both groups at 1 week 
postoperatively compared to the baseline, but this significance disappeared at 2 
and 6 months. LDL did not show any significant changes after surgery in either 
group. Triglyceride levels increased in both groups at 1 week after surgery 
compared to preoperative levels but were only significant in the POSE group (p = 
0.01). At 2 and 6 months postoperatively, there were no significant changes in 
triglyceride levels compared to preoperative levels. 
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 POSE RYGB 
Pre-op total cholesterol (mmol/L) 4.1 (± 0.3) 4.3 (± 1.13) 
Post-op (1 w) total cholesterol 
(mmol/L) 
3.7 (± 0.5) 3.8 (± 0.7) 
Post-op (2 m) total cholesterol 
(mmol/L)  
3.9 (± 0.5) 4.4 (± 0.9) 
Post-op (6 m) total cholesterol 
(mmol/L) 
4.4 (± 0.9) 4.4 (± 1.0) 
Pre-op LDL (mmol/L) 2.03 (± 0.35) 2.4 (± 1.02) 
Post-op (1 w) LDL (mmol/L) 1.9 (± 0.4) 2.0 (± 0.6) 
Post-op (2 m) LDL (mmol/L) 1.9 (± 0.3) 2.6 (± 0.7) 
Post-op (6 m) LDL (mmol/L) 2.7 (± 0.7) 2.5 (± 0.7) 
Pre-op HDL (mmol/L) 1.6 (± 0.8) 1.2 (± 0.3) 
Post-op (1 w) HDL (mmol/L) 1.1 (± 0.4) 0.9 (± 1.0) 
Post-op (2 m) HDL (mmol/L) 1.5 (± 0.4) 1.2 (± 0.2) 
Post-op (6 m) HDL (mmol/L) 1.6 (± 0.6) 1.4 (± 0.4) 
Pre-op triglyceride (mmol/L) 0.92 (± 0.68) 1.36 (± 0.8) 
Post-op (1 w) triglyceride 
(mmol/L) 
1.6 (± 0.4) 1.4 (± 0.5) 
Post-op (2 m) triglyceride 
(mmol/L) 
1.0 (± 0.3) 1.4 (± 0.6) 
Post-op (6 m) triglyceride 
(mmol/L) 
1.1 (± 0.6) 1.3 (± 0.9) 
 
Table 4.3 Circulating lipid levels before and after (1 week, 2 months and 6 
months) POSE and RYGB surgery 
Pre-op = preoperatively, Post-op = postoperatively, w = week, m = month. Data 
are expressed as mean and standard deviation. 
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4.3.4 Glucose, insulin and GLP-1 secretions 
POSE patients had higher fasting glucose levels than RYGB patients (8.98 ± 4.61 
and 5.81 ± 1.29 mmol/L, respectively; p = 0.06). In both groups, fasting glucose 
levels did not differ significantly between preoperative and 1 week, 2 month or 6 
month postoperative levels. There were no significant changes in postprandial 
glucose levels (30, 120 and 180 minutes) postoperatively at 1 week, 2 months and 
6 months compared to preoperative levels in either POSE or RYGB groups (Table 
4.4, Figures 4.5 and Figure 4.6). 
In the POSE group, there was no significant change in postoperative basal insulin 
levels or HOMA at 1 week, 2 months and 6 months compared to the preoperative 
level; however, in RYGB patients, significant decreases in basal insulin levels were 
apparent at 1 week and 6 months postoperatively compared to the preoperative 
level (p < 0.05). HOMA also decreased significantly postoperatively in RYGB 
patients compared to the baseline (p < 0.05; Table 4.5, Figures 4.7 and 4.8). 
Prior to surgery, postprandial insulin levels (30, 120 and 180 minutes) were 
comparable between POSE and RYGB patients (Table 4.6). Postprandial insulin 
response at 30, 120 and 180 minutes showed no significant difference before and 
1 week, 2 months and 6 months after the POSE procedure (Figures 4.9 A, 4.10 A, 
4.11 A and 4.12 A). No significant difference in 30-minute postprandial insulin 
response showed at 1 week, however, a significant drop in 120-minute 
postprandial insulin response (p = 0.02) was shown at 1 week after the RYGB 
procedure (Figure 4.10 B). The early (30 minute) postprandial insulin response 
increased, and the late (120 minute) postprandial insulin response decreased 
following RYGB surgery, and reached significance (p < 0.05) at 2 and 6 months 
(Figures 4.11 B & 4.12 B). The AUC0-180 of insulin in response to the meal was 
not changed post-POSE compared to preoperatively (Figure 4.13 A and Table 4.7). 
However, it was increased post-RYGB at 2 and 6 months compared to 
preoperatively but did not reach significance (p > 0.05) (Figure 4.13 B and Table 
4.7). 
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Fasting and postprandial (30, 120 and 180 minute) GLP-1 levels were comparable 
between POSE and RYGB patients preoperatively (Figure 4.14). No changes were 
seen in postoperative fasting and postprandial GLP-1 levels compared to the 
baseline in POSE patients (Figures 4.15 A, 4.16 A and 4.17 A). In addition, the 
AUC0-180 of GLP-1 in response to the meal did not differ before and after (1 week, 
2 months and 6 months) the POSE procedure (Figure 4.18 A). However, 
postprandial GLP-1 at 30 minutes showed significant elevation (p < 0.05) post-
RYGB procedure at 1 week, 2 months and 6 months compared to the baseline 
(Figures 4.15 B, 4.16 B and 4.17 B). Consistently, there was significant elevation 
in the AUC0-180 of GLP-1 in response to the meal after (1 week, 2 months and 6 
months) RYGB compared to the preoperative level (Figure 4.18 B). 
  
 109 
 POSE RYGB 
Pre-op glucose (mM) 
Fasting 
Postprandial 30 m 
Postprandial 2 h 
Postprandial 3 h 
 
 
8.98 (± 4.6) 
9.9 (± 5.0) 
11.1 (± 7.8) 
9.1 (± 7.8) 
 
5.8 (± 1.3) 
6.5 (± 1.4) 
6.3 (± 1.2) 
5.7 (± 0.8) 
Post-op (1 week) glucose (mM) 
Fasting 
Postprandial 30 m 
Postprandial 2 h 
Postprandial 3 h 
 
 
8.6 (± 4.2) 
8.7 (± 6.1) 
9.2 (± 7.3) 
9.3 (± 6.8) 
 
 
6.4 (± 2.9) 
8.7 (± 3.1) 
6.1 (± 3.1) 
6.7 (± 3.2) 
Post-op (2 month) glucose (mM) 
Fasting 
Postprandial 30 m 
Postprandial 2 h 
Postprandial 3 h 
 
 
7.8 (± 3.2) 
9.1 (± 5.2) 
10.2 (± 6.8) 
9.3 (± 6.3) 
 
5.6 (± 1.7) 
7.2 (± 1.9) 
4.5 (± 0.5) 
5.0 (± 1.1) 
Post-op (6 month) glucose (mM) 
Fasting 
Postprandial 30 m 
Postprandial 2 h 
Postprandial 3 h 
 
 
6.2 (± 2.0) 
8.4 (± 4.5) 
8.2 (± 7.4) 
5.5 (± 1.2) 
 
5.7 (± 2.2) 
8.4 (± 3.9) 
5.5 (± 3.7) 
5.5 (± 3.0) 
 
Table 4.4 Fasting and postprandial glucose levels before and after (1 week, 
2 months and 6 months) POSE and RYGB procedures 
Data are expressed as mean and standard deviation. Pre-op = preoperatively, 
post-op = postoperatively, m = minute, h = hour. 
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Figure 4.5 Fasting and postprandial (30, 120 and 180 minutes) glucose 
levels prior to (A) and 1 week (B), 2 months (C) and 6 months (D) after POSE 
surgery 
There were no significant changes in fasting and postprandial glucose levels 
before and after (1 week, 2 months and 6 months) the POSE procedure. Data are 
expressed as median and interquartile range. 
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Figure 4.6 Fasting and postprandial (30, 120 and 180 minutes) glucose 
levels prior to (A) and 1 week (B), 2 months (C) and 6 months (D) after RYGB 
surgery 
There were no significant changes in fasting and postprandial glucose levels 
before and 1 week, 2 months and 6 months after the RYGB procedure. Data are 
expressed as median and interquartile range. 
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 POSE RYGB 
HOMA-IR 
Pre-op 
1 w post-op 
2 m post-op 
6 m post-op 
 
Fasting insulin 
(mIU/L) 
Pre-op 
1 w post-op 
2 m post-op 
6 m post-op 
 
 
1.4 (0.4–2.7) 
1.9 (0.9–2.7) 
1.1 (0.6–3.4) 
0.9 (0.4–1.5) 
 
 
4.9 (2.3–6.4) 
5.7 (3.5–7.0) 
5.0 (2.7–7.6) 
4.1 (1.6–6.0) 
 
2.5 (1.8–3.8) 
1.6 (1.0–2.6) 
2.2 (1.1–3.1) 
1.2 (0.5–1.7) 
 
 
9.8 (8.3–13.9) 
6.9 (4.5–8.2) 
9.2 (5.5–13.9) 
5.5 (2.6–6.2) 
 
Table 4.5 HOMA-IR and fasting insulin levels before and after POSE and 
RYGB procedures 
Data are expressed as median and interquartile range. HOMA-IR = homeostatic 
model assessment – insulin resistance, pre-op = preoperatively, post-op = 
postoperatively, w = week, m = month. 
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Figure 4.7 Fasting insulin level prior to and following (1 week, 2 months and 
6 months) POSE (A) and RYGB (B) procedures 
Fasting insulin plasma levels showed no significant changes before and after (1 
week, 2 months and 6 months) the POSE procedure (p > 0.05). However, there 
was a significant decrease in fasting insulin levels at 1 week and 6 months after 
the RYGB procedure compared to the preoperative level (p < 0.05). Data are 
expressed as median and interquartile range. Pre-op: preoperatively, 1wPO: 1 
week postoperatively, 2mPO: 2 months postoperatively, 6mPO: 6 months 
postoperatively. 
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Figure 4.8 HOMA-IR before and after (1 week, 2 months and 6 months) POSE (A) 
and RYGB (B) procedures 
There were no significant changes in HOMA-IR following POSE surgery compared to 
preoperatively. There was a significant reduction in HOMA-IR at 1 week (p = 0.04) and 
6 months (p = 0.02) after RYGB surgery compared to preoperatively (p < 0.05). Data are 
expressed as median and interquartile range. Pre-op: preoperatively, 1wPO: 1 week 
postoperatively, 2mPO: 2 months postoperatively, 6mPO: 6 months postoperatively, 
HOMA-IR: homeostasis model assessment – insulin resistance. 
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 POSE RYGB 
Pre-op insulin (mIU/L) 
Fasting 
Postprandial 30 m 
Postprandial 2 h 
Postprandial 3 h 
 
 
4.9 (2.3–6.4) 
19.0 (9.1–29.8) 
17.8 (3.4–30.4) 
5.5 (1.5–12.7) 
 
9.8 (8.3–13.9) 
32.6 (21.2–86.6) 
27.4 (21.7–35.6) 
15 (9.0–22.7) 
Post-op (1 week) insulin (mIU/L) 
Fasting 
Postprandial 30 m 
Postprandial 2 h 
Postprandial 3 h 
 
 
5.7 (3.5–7.0) 
27.4 (4.6–31.9) 
15.5 (4.1–27.1) 
9.0 (2.7–15.9) 
 
 
6.9 (4.5–8.2) 
51.2 (26.6–100.2) 
9.1 (5.9–23.9) 
6.8 (4.4–11.6) 
Post-op (2 month) insulin (mIU/L) 
Fasting 
Postprandial 30 m 
Postprandial 2 h 
Postprandial 3 h 
 
 
5.0 (2.7–7.6) 
21.3 (9.1–44.2) 
11.5 (2.2–25.7) 
4.1 (1.5–12.1) 
 
9.2 (5.1–13.9) 
137 (74.2–228.5) 
7.9 (4.1–20.4) 
7.8 (3.4–8.8) 
Post-op (6 month) insulin (mIU/L) 
Fasting 
Postprandial 30 m 
Postprandial 2 h 
Postprandial 3 h 
 
 
4.1 (1.7–6.0) 
25.5 (3.4–36.1) 
8.1 (1.7–32.0) 
3.8 (1.3–13.0) 
 
5.5 (2.6–6.2) 
117.4 (117.4–147) 
5.1 (3.6–10.0) 
4.4 (2.8–7.1) 
 
Table 4.6 Fasting and postprandial insulin levels before and after (1 week, 
2 months and 6 months) POSE and RYGB procedures 
Data are expressed as median and interquartile range. Pre-op = preoperatively, 
post-op = postoperatively, m = minute, h = hour. 
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Figure 4.9 Preoperative insulin responses to a meal in POSE (A) and RYGB 
(B) patients 
In the POSE and RYGB groups, 30-minute levels of postprandial insulin compared 
to fasting were significantly elevated (p = 0.028 and 0.005, respectively). Further, 
120-minute postprandial levels were comparable to 30-minute postprandial 
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levels in both groups (p > 0.05). The delta changes of insulin levels from baseline 
to 30-minute postprandial, and from 30 to 120 minutes postprandial in POSE 
patients were comparable to those in RYGB patients (p > 0.05). Data are expressed 
as median and interquartile range. m = minute. 
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Figure 4.10 One-week postoperative insulin response to a meal in POSE (A) 
and RYGB (B) patients 
There were no significant changes in postprandial (30, 120 and 180 minute) 
insulin levels 1 week after POSE compared to preoperative levels. One week after 
RYGB, 30-minute postprandial insulin levels were comparable to preoperative 
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levels; however, 120-minute postprandial insulin levels decreased significantly (p 
= 0.02) compared to preoperative levels. The delta change of insulin levels from 
baseline to 30-minute postprandial was comparable between POSE and RYGB; 
however, the delta change from 30 to 120 minutes was significantly greater in 
RYGB compared to POSE (p = 0.02). Data are expressed as median and 
interquartile range. 
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Figure 4.11 Two-month postoperative insulin responses to a meal in POSE 
(A) and RYGB (B) patients 
There were no significant changes in postprandial (30, 120 and 180 minute) 
insulin levels 2 months after POSE compared to preoperative levels. Two months 
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after RYGB, 30-minute postprandial insulin levels increased significantly (p = 
0.02), and 120-minute postprandial insulin levels decreased significantly (p = 
0.04) compared to preoperative levels. The delta changes of insulin levels from 
baseline to 30-minute postprandial and from 30 to 120 minutes postprandial for 
RYGB were significantly greater than those for POSE (p = 0.001). Data are 
expressed as median and interquartile range. 
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Figure 4.12 Six-month postoperative insulin responses to a meal in POSE (A) 
and RYGB (B) patients 
There were no significant changes in postprandial (30, 120 and 180 minute) 
insulin levels 6 months after POSE compared to preoperative levels. Six months 
after RYGB, 30-minute postprandial insulin levels increased significantly (p = 
0.05), and 120-minute postprandial insulin levels decreased significantly (p = 
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0.04) compared to preoperative levels. The delta changes of insulin levels from 
baseline to 30-minute postprandial and from 30 to 120 minutes postprandial for 
RYGB were significantly greater than those for POSE (p = 0.002 and 0.001, 
respectively). Data are expressed as median and interquartile range. 
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 POSE RYGB 
 
AUC insulin 
 
Pre-op 
1 w post-op 
2 m post-op 
6 m post-op 
 
 
 
2826 (± 1786) 
2847 (± 1841) 
2755 (± 2144) 
2736 (± 2078) 
 
 
 
 
 
 
5819 (± 2898) 
5894 (± 4010) 
10285 (± 5317) 
7583 (± 3865) 
 
 
 
Table 4.7 Area under the curve for insulin response to a meal before and 
after (1 week, 2 months and 6 months) POSE and RYGB surgery 
Data are expressed as mean and standard deviation. AUC = area under the curve, 
pre-op= preoperatively, post-op = postoperatively, w = week, m = month. 
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Figure 4.13 Area under the curve for insulin response to a meal before and 
after (1 week, 2 months and 6 months) POSE (A) and RYGB (B) surgery 
The AUC for insulin response to the meal did not differ before and after (1 week, 
2 months and 6 months) POSE surgery (A). However, the AUC for insulin response 
increased after RYGB at 2 and 6 months compared to preoperatively (B) but did 
not reach significance (p = 0.09 and 0.06, respectively). Data are expressed as 
median and interquartile range. Pre-op: preoperatively, 1wPO: 1 week 
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postoperatively, 2mPO: 2 months postoperatively, 6mPO: 6 months 
postoperatively. 
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 POSE RYGB 
Pre-op GLP-1 (PM) 
Fasting 
Postprandial 30 m 
Postprandial 2 h 
Postprandial 3 h 
 
 
5.3 (5.2–5.6) 
10.0 (7.0–12.8) 
9.8 (7.0–12.8) 
6.5 (6.1–7.7) 
 
4..9 (4.2–5.9) 
7.0 (6.6–8.2) 
6.2 (5.2–9.4) 
5.9 (4.4–7.1) 
Post-op (1 week) GLP-1 (PM) 
Fasting 
Postprandial 30 m 
Postprandial 2 h 
Postprandial 3 h 
 
 
5.4 (5.2–5.9) 
10.4 (7.6–13.0) 
8.5 (6.3–10.5) 
6.0 (5.8–10.4) 
 
 
5.3 (4.5–6.6) 
79.4 (13.3–99.2) 
10.6 (6.8–26.5) 
6.3 (5.2–14.4) 
Post-op (2 month) GLP-1 (PM) 
Fasting 
Postprandial 30 m 
Postprandial 2 h 
Postprandial 3 h 
 
 
5.6 (3.8–7.1) 
8.8 (7.7–13.8) 
6.5 (5.3–14.7) 
5.7 (4.6–16.8) 
 
4.5 (4.1–6.1) 
100.5 (81.5–111.6) 
11.1 (5.3–15.8) 
5.4 (4.5–8.5) 
Post-op (6 month) GLP-1 (PM) 
Fasting 
Postprandial 30 m 
Postprandial 2 h 
Postprandial 3 h 
 
 
4.3 (4.1–5.3) 
8.1 (6.8–10.2) 
5.6 (4.4–6.5) 
4.9 (4.2–5.8) 
 
4.3 (4.0–4.3) 
83.6 (71.9–91.7) 
6.3 (5.2–13.9) 
4.4 (4.0–5.1) 
 
Table 4.8 Fasting and postprandial GLP-1 levels after (1 week, 2 months and 
6 months) POSE and RYGB procedures 
Data are expressed as median and interquartile range. Pre-op = preoperatively, 
post-op = postoperatively, m = minute, h = hour. 
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Figure 4.14 Preoperative fasting and postprandial (30, 120 and 180 
minutes) GLP-1 levels for POSE (A) and RYGB (B) procedures 
Fasting and postprandial (30, 120 and 180 minute) GLP-1 levels were comparable 
between POSE and RYGB patients preoperatively. Data are expressed as median 
and interquartile range. 
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Figure 4.15 One-week postoperative fasting and postprandial (30, 120 and 
180 minutes) GLP-1 levels for POSE (A) and RYGB (B) procedures 
There were no significant changes in fasting and postprandial (30, 120 and 180 
minutes) GLP-1 levels 1 week after POSE compared to preoperative levels (p > 
0.05). One week after RYGB, there were no significant changes in fasting and 120- 
and 180-minute postprandial GLP-1 levels compared to preoperative levels; 
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however, 30-minute postprandial GLP-1 increased significantly (p = 0.05). The 
delta change of GLP-1 levels from baseline to 30 minutes postprandial for RYGB 
was significantly greater than that for POSE (p = 0.02). Data are expressed as 
median and interquartile range. 
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Figure 4.16 Two-month postoperative fasting and postprandial (30, 120 
and 180 minutes) GLP-1 levels for POSE (A) and RYGB (B) procedures 
There were no significant changes in fasting and postprandial (30, 120 and 180 
minutes) GLP-1 levels 2 months after POSE compared to preoperative levels (p > 
0.05). Two months after RYGB, there were no significant changes in fasting and 
120- and 180-minute postprandial GLP-1 levels compared to preoperative levels; 
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however, 30-minute postprandial GLP-1 increased significantly (p = 0.01). The 
delta change of GLP-1 levels from baseline to 30 minutes postprandial for RYGB 
was significantly greater than that for POSE (p = 0.001). Data are expressed as 
median and interquartile range. 
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Figure 4.17 Six-month postoperative fasting and postprandial (30, 120 and 
180 minutes) GLP-1 levels for POSE (A) and RYGB (B) procedures 
There were no significant changes in fasting and postprandial (30, 120 and 180 minutes) 
GLP-1 levels 6 months after POSE compared to preoperative levels (p > 0.05). Six months 
after RYGB, there were no significant changes in fasting and 120- and 180-minute 
postprandial GLP-1 levels compared to preoperative levels; however, 30-minute 
postprandial GLP-1 increased significantly (p = 0.01). The delta change of GLP-1 levels 
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from baseline to 30-minute postprandial for RYGB was significantly greater than that 
for POSE (p = 0.001). Data are expressed as median and interquartile range. 
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 POSE RYGB 
 
AUC GLP-1 
 
Pre-op 
1 w post-op 
2 m post-op 
6 m post-op 
 
 
 
1383 (± 184) 
1614 (± 397) 
1893 (± 1566) 
1184 (± 303) 
 
 
 
 
 
2043 (± 279) 
5497 (± 3712) 
7224 (± 1063) 
5733 (± 1683) 
 
 
 
Table 4.9 Area under the curve for GLP-1 response to meal before and after 
(1 week, 2 months and 6 months) POSE and RYGB surgery 
Data are expressed as mean and standard deviation. AUC = area under the curve, 
pre-op = preoperatively, post-op = postoperatively, w = week, m = month. 
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Figure 4.18 Area under the curve for GLP-1 response to meal before and 
after (1 week, 2 months and 6 months) POSE (A) and RYGB (B) surgery 
The area under the curve for GLP-1 response did not differ before and after (1 
week, 2 months and 6 months) POSE surgery (A). However, the AUC for GLP-1 
response increased significantly after RYGB surgery (1 week: p = 0.01; 2 months: 
p = 0.03; 6 months: p = 0.04) compared to preoperatively (B). Data are expressed 
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as median and interquartile range. Pre-op: preoperatively, 1wPO: 1 week 
postoperatively, 2mPO: 2 months postoperatively, 6mPO: 6 months 
postoperatively. 
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4.3.5 Adipokine concentrations 
Table 4.10 shows circulating leptin and adiponectin levels before and after (1 
week, 2 months and 6 months) POSE and RYGB procedures. Leptin levels were 
reduced significantly at 1 week after POSE and RYGB surgeries compared to the 
preoperative values (p = 0.028 and p = 0.005, respectively). Further significant 
reduction was seen in RYGB patients at 2 and 6 months postoperatively. Two and 
six months after the POSE procedure, leptin levels were also significantly reduced 
compared to the baseline, but the reduction was greater at 1 week postoperatively 
(Figure 4.19 A and B). 
Adiponectin levels showed no significant difference before and after the POSE 
procedure (Figure 4.20 A). For RYGB, a trend of increasing adiponectin was seen 
at 2 and 6 months postoperatively compared to the baseline level (Figure 4.20 B). 
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 POSE RYGB 
 
Leptin (ng/ml) 
Pre-op 
1 w post-op 
2 m post-op 
6 m post-op 
 
Adiponectin (g/ml) 
Pre-op 
1 w post-op 
2 m post-op 
6 m post-op 
 
 
 
65.0 (49.9–114.2) 
131.0 (21.4–78.0) 
49.2 (18.4–73.2) 
46.4 (21.3–71.3) 
 
 
7.2 (5.3–10.5) 
6.2 (5.0–10.6) 
8.5 (5.4–12.7) 
7.6 (6.3–9.5) 
 
 
78.4 (50.0–120.0) 
39.7 (32.6–51.7) 
32.5 (27.1–42.3) 
31.8 (8.2–59.3) 
 
 
6.3 (3.9–8.6) 
5.9 (4.8–10.2) 
8.0 (6.3–14.7) 
16.4 (6.6–28.1) 
 
Table 4.10 Leptin and adiponectin levels prior to and following (1 week, 2 
months and 6 months) POSE and RYGB procedures 
Data are expressed as median and interquartile range. Pre-op = preoperatively, 
post-op = postoperatively, w = week, m = month. 
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Figure 4.19 Leptin levels before and after (1 week, 2 months and 6 months) 
POSE (A) and RYGB (B) surgery 
 141 
Leptin concentration decreased significantly 1 week after POSE (p = 0.02) and 
RYGB (p = 0.005) procedures, and a further reduction occurred at 2 (p = 0.018) 
and 6 (p = 0.018) months after the RYGB procedure. Although a significant 
decrease in leptin level appeared at 1 week and 2 months (p < 0.05) compared to 
the preoperative level, this significance had disappeared at 6 months (p= 0.07) in 
POSE patients. Data are expressed as median and interquartile range. Pre-op: 
preoperatively, 1wPO: 1 week postoperatively, 2mPO; 2 months postoperatively, 
6mPO: 6 months postoperatively. 
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Figure 4.20 Adiponectin levels before and after (1 week, 2 months and 6 
months) POSE (A) and RYGB (B) surgery 
Adiponectin levels for POSE (A) and RYGB (B) patients. The postoperative level at 
1 week, 2 months and 6 months did not differ from the preoperative level in POSE 
and RYGB patients (p > 0.05). Data are expressed as median and interquartile 
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range. Pre-op: preoperatively, 1wPO: 1 week postoperatively, 2mPO: 2 months 
postoperatively, 6mPO: 6 months postoperatively. 
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4.4 Discussion 
POSE is a new less invasive and incisionless surgical weight-loss technique. This 
study investigated the difference between the outcome of POSE and RYGB 
surgeries with regard to weight loss and changes in GLP-1 and metabolic markers. 
Significant weight loss was recorded even at 1 week, and increased at 2 and 6 
months after RYGB. This result is consistent with other studies that showed 
steady weight loss after RYGB which was maintained beyond 6 months up to 10 
years [319]. Conversely, the weight loss after POSE was less than that seen after 
RYGB and had reached a plateau at 2 months postoperatively. This result conflicts 
with those reported by Espinos et al., who showed effective weight loss at 6 
months following the POSE procedure [314]. Also, EWL was greater in the study 
of Espinos et al. This difference in weight-loss result can be explained by the 
difference in BMI; in this study, the pre-surgical BMI was greater (mean 41.3 
kg/m2) than that of Espinos et al. (mean 36.7 kg/m2). In addition, the sample size 
was greater in the study of Espinos et al. (n = 45) than in this study (n = 6), with 
two diabetic patients included in this study. It seems that POSE may be more 
effective in patients with a lower BMI and without complications. 
No significant improvement was seen in fasting and postprandial glucose levels 
after POSE at any of the time-points in either the non-diabetic or diabetic patients. 
However, at 6 months, the fasting glucose level was reduced but not significantly; 
this reduction could be secondary to weight loss. At 6 months, one diabetic patient 
reported that her anti-diabetic medication dose had been reduced 2 months after 
having the POSE procedure. Also, neither fasting nor postprandial insulin 
responses were affected by POSE. Furthermore, no improvement in fasting or 
postprandial active GLP-1 levels was recorded, perhaps explaining the lack of 
changes in insulin response postoperatively. 
The only other data on patients being studied after POSE was reported in abstract 
form [320]. They showed significant improvement in glucose/insulin ratio at 2 
and 6 months after the POSE procedure. The study also showed that in the 
postprandial state, orexigenic ghrelin was reduced significantly, and anorexigenic 
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PYY increased at 2 and 6 months post-POSE surgery. The authors concluded that 
significant weight loss was achieved by an increase in the satiety response at 2 
and 6 months after POSE [321]. 
We show that, while there was no change following RYGB in fasting and 
postprandial glucose level, fasting insulin concentrations were lower, and insulin 
sensitivity improved. Furthermore, in these patients, postprandial GLP-1 levels 
increased significantly from the first week, and stayed elevated at 2 and 6 months, 
perhaps explaining the improvement in insulin secretion and sensitivity. The two 
diabetic patients who underwent RYGB reduced their anti-diabetic medications 
at 1 week and 2 months, and had stopped taking any medication by 6 months after 
surgery. This is in accordance with previous studies showing early improvement 
in glycaemia and insulin sensitivity, and remission of diabetes after RYGB surgery, 
even before achieving significant weight loss, perhaps related to an acute increase 
in postprandial GLP-1 secretion [322, 323]. Thus, unlike the results observed for 
RYGB, the early improvement in insulin and glycaemia independent of weight loss 
that could be partially due to acute alteration in gut hormones such as GLP-1 was 
not seen after the POSE procedure, though late improvement in fasting glucose 
was observed (6 months) secondary to weight reduction. 
Leptin decreased significantly 1 week after POSE, but this was attributed to 
weight loss brought about by the low calorie intake of the patients who were on a 
liquid diet for 2 weeks until discomfort from the surgical procedure disappeared. 
However, leptin stayed lower than pre-surgery levels at 2 and 6 months, 
suggesting some loss of fat mass. Adiponectin levels remained unchanged 
following POSE, reflecting the lack of effect on insulin sensitivity. 
After RYGB, the leptin level was also significantly decreased after 1 week, and the 
suppression was greater at 2 and 6 months. Adiponectin levels increased 
gradually after RYGB but did not reach significance. This is in accordance with a 
previous study [324, 325]. No changes in lipid parameters were apparent after 
either type of surgery. 
In conclusion, our study revealed that although the POSE procedure is a less 
invasive and risky technique than RYGB, it is not as effective as RYGB with regard 
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to weight loss, improved glycaemic homeostasis and insulin secretion, and an 
increase in postprandial GLP-1 hormone. Further studies are required in a larger 
sample cohort and for longer periods post-surgery to carefully compare the 
advantages of this new procedure to RYGB in its ability to facilitate weight loss 
along with beneficial effects on metabolism. The POSE procedure may be more 
effective for healthy obese patients with a BMI between 30 and 35 with no 
comorbidities. 
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Chapter 5 
 
Post-absorptive 
and postprandial 
GLP-1 in an Arab 
female population 
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5.1 Introduction 
The prevalence of obesity has increased significantly throughout the world during 
the last three decades. The countries of the Middle East in particular have the 
highest incidence of obesity and type 2 diabetes globally [326-328]. 
In Saudi Arabia, only 19.9% of Saudis attending primary healthcare clinics have a 
normal body weight, while 49.9% are obese. This rate reflects a rise from that 
reported in the late 1990s (35.6%) [329]. In Kuwait, adolescent obesity in 2002 
was 19.9%, already exceeding that of the United States (15.3%) [330, 331]. 
Kuwait also has the highest rate of type 2 diabetes among the Arab countries 
[332]. The specific reasons for this phenomenon have not as yet been completely 
elucidated. 
An imbalance between energy intake and expenditure is an important influence 
contributing to obesity, so any factor that affects this balance could result in 
excess weight [333]. Lack of exercise and a sedentary lifestyle may thus 
contribute to the high rates of obesity. Rising income levels since the discovery of 
oil have led to a sedentary lifestyle, with an increase in the usage of motor 
vehicles, and diets high in fat and carbohydrates [334]. 
Whether obesity in this region is predominantly due to lower quality of food and 
sedentary lifestyle, or whether there may be other physiological mediators to this 
rise is of intense current research. A possible candidate that may explain to some 
extent the increased susceptibility to obesity and its associated metabolic 
diseases is the hormones of the gut–brain axis, such as GLP-1. Whether GLP-1 is 
secreted to a lesser extent either post-absorptively or postprandially and 
therefore affects satiety and insulin sensitivity in these individuals needs to be 
investigated. The current hypothesis is that impaired secretion of postprandial 
GLP-1 contributes to obesity of people living in the Middle East. 
The aim of this study was to investigate fasting and postprandial GLP-1 secretion 
in normal-weight, overweight and obese individuals living in countries of the 
Middle East. 
 
 149 
5.2 Methods 
Forty female subjects of mixed ethnicity without documented metabolic diseases 
were recruited for this study. Twenty-seven Arab subjects living in Qatar were 
studied at the Clinical Research Centre (CRC) of the ADLQ. Thirteen subjects of 
mixed ethnicity (Caucasians, South Asians, Arabs and Africans) living in London 
were concomitantly studied at the CRC at UCL. All subjects provided written 
informed consent, and the studies were approved by the relevant national ethics 
committees. 
Subjects attended in the morning after an overnight fast of at least 8–10 hours. 
Blood pressure, pulse, height (m) and weight (kg) were measured; body fat was 
measured by bioimpedance, and expressed as a % of body weight. BMI was 
calculated (kg/m2). 
Blood was collected during fasting and 30 and 120 minutes after consuming a 
standard 388.6-kcal liquid mixed meal (17.4 g of fat, 40 g of carbohydrate and 18 
g of protein). The fasting samples were used to measure GLP-1, insulin, proinsulin, 
total cholesterol, LDL, HDL, triglycerides, glucose, adiponectin and leptin, whereas 
the postprandial samples were used to measure GLP-1, insulin, proinsulin and 
glucose. A specific DPP-IV inhibitor was added to the blood tubes that were used 
to determine GLP-1. 
Active GLP-1 (Millipore, Billerica, MA, USA), insulin, glucose, lipids and adipokine 
levels were determined as mentioned previously in sections 2.2.1, 2.2.2 and 
2.2.4. Proinsulin was also measured by ELISA (Mercodia, Sweden). 
All assays had inter- and intra-assay coefficients of variation (CV) less than 10%. 
Normality of results was tested; parametric tests were used for normally 
distributed data, and non-parametric analysis used for skewed data (see section 
2.5). 
 
 150 
5.3 Results 
5.3.1 Subjects’ characteristics 
The subject characteristics of the population are shown in Table 5.1. Subjects in 
both groups were euglycaemic and normoinsulinaemic in the basal state. 
However, subjects living in Doha were significantly hyperinsulinaemic in the 
postprandial state at 30 and 120 minutes, compared to the London cohort (p < 
0.001), despite being significantly younger; this difference in postprandial insulin 
levels between the two groups is illustrated in Figure 5.1. 
The lipid profile of the London cohort showed greater levels of total cholesterol 
as well as of HDL, but no differences in triglycerides and LDL. 
Of note were the especially high levels of systemic leptin in the Qatari cohort (p < 
0.001), suggesting a high body fat mass, although both groups had comparable 
BMI (p = 0.61). 
The cohort living in Doha were then investigated further by grouping them into 
those of normal-weight, overweight and those who were obese by WHO criteria. 
Table 5.2 shows the characteristics of Arab subjects living in Qatar. Subjects were 
divided into three categories: 12 subjects of normal weight (mean (± SD), BMI = 
21.4 ± 2 kg/m2), eight overweight subjects (BMI = 27 ± 1.6 kg/m2) and seven 
obese subjects (BMI = 32.5 ± 1.6 kg/m2). Subjects were matched for age in the 
normal-weight group (mean (± SD), 29.5 ± 5.5 years), overweight group (27.1 ± 
4.4 years) and obese group (30 ± 5.3 year). Obese subjects had the highest body 
fat percentage (mean (± SD), 42.1 ± 3.2%) compared to overweight (36.2 ± 2.7%) 
and normal-weight (29.4 ± 4.7%) subjects. All subjects were normotensive, 
euglycaemic and normolipidaemic. The obese subjects were hyperinsulinaemic 
(insulin and HOMA-IR median and interquartile range were 15.5 (5.8–19.8) and 
3.1 (1.2–4.22) mIU/L, respectively), whereas normal-weight and overweight 
subjects were normoinsulinaemic (insulin median and interquartile range: 4.8 
(3.5–5.2) and 5.2 (4.2–6.1) mIU/L, respectively; HOMA-IR median and 
interquartile range: 0.97 (0.67–1.16) and 1.12 (0.85–1.38), respectively). 
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Variables Living in London 
(n = 13) 
Living in Qatar 
(n = 27) 
 
p value 
Age (years) 28.9 ± 5.1 38.2 ± 13.5 0.02 
 
Weight (kg) 66.4 ± 14.7 
 
64.3 ± 14.3 
 
0.67 
BMI (kg/m2) 25.9 ± 4.9 24.0 ± 5.8 
 
0.61 
Glucose 
(mmol/L) 
 
4.6 ± 0.3 5.0 ± 0.7 0.05 
Insulin (mIU/L) 5.1 (4–7) 5.7 (3.6–7.1) 0.9 
PP 30 min 
insulin (mIU/L) 
50.5 (35–63) 20.2 (13.2–28.7) < 0.001 
PP 120 min 
insulin (mIU/L) 
31.2 (23.6–53.1) 3.8 (2.7–7.0) < 0.001 
HOMA-IR 1.12 (0.8–1.4) 
 
1.2 (0.7–1.5) 
 
0.82 
Total 
cholesterol 
(mmol/L) 
 
3.6 ± 0.7 4.7 ± 1 0.001 
Triglyceride 
(mmol/L) 
 
0.60 (0.4–0.8) 0.6 (0.5–1) 0.42 
HDL cholesterol 
(mmol/L) 
 
1.22 ± 0.29 1.79 ± 0.73 0.01 
LDL cholesterol 
(mmol/L) 
 
2.1 ± 0.5 2.6 ± 0.9 0.1 
Leptin (ng/L) 30.8 (17.5–53) 5.9 (3.8–11.5) < 0.001 
Table 5.1 Subjects' characteristics 
Data are expressed as mean ± standard deviation or median (interquartile range). PP: 
postprandial, BMI: body mass index, HOMA-IR: homeostatic model assessment – insulin 
resistance, HDL: high-density lipoprotein, LDL: low-density lipoprotein.  
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Figure 5.1 Fasting and postprandial (30 and 120 minutes) insulin level in 
subjects living in London (A) and subjects living in Qatar (B) 
Fasting insulin levels were within the normal range and were comparable 
between the two groups (p = 0.9). However, postprandial insulin levels were 
significantly higher in the group living in Qatar, especially at 120 minutes (p < 
0.001). Data are expressed as median and interquartile range. min: minutes. 
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Variables 
Normal weight 
(n = 12) 
Overweight 
(n = 8) 
Obese 
(n = 7) 
Age (years) 29.5 ± 5.5 27.1 ± 4.4 30 ± 5.3 
Weight (kg) 54.1 ± 5.7 68.4 ± 5.6 85.2 ± 11.3 
BMI (kg/m2) 21.4 ± 2.0 27 ± 1.6 32.5 ± 1.6 
Body fat % 29.4 ± 4.7 36.2 ± 2.7 *42.1 ± 3.2 
SBP (mm Hg) 108.4 ± 11.5 108 ± 7.8 116 ± 6.1 
DBP (mm Hg) 70 ± 5.8 70.2 ± 7.3 74.1 ± 7.8 
Glucose (mmol/L) 4.53 ± 0.4 4.74 ± 0.29 4.53 ± 0.14 
Insulin (mIU/L) 4.8 (3.5–5.2) 5.2 (4.2–6.1) *15.5 (5.8–19.8) 
HOMA-IR 0.97 (0.67–1.16) 1.12 (0.85–1.38) *3.1 (1.2–4.22) 
Total chol (mmol/L) 3.6 ± 0.63 3.3 ± 0.82 3.9 ± 0.75 
Triglyceride (mmol/L 0.52 (0.46–0.66) 0.53 (0.36–0.8) 0.83 (0.67–1.07) 
HDL chol (mmol/L) 1.28 ± 0.29 1.31 ± 0.32 1.03 ± 0.22 
LDL chol (mmol/L) 2.1 ± 0.4 1.82 ± 0.52 2.47 ± 0.56 
Leptin 
(ng/ml) 
21.3 (13.4–33.0) 31.8 (28.3–43.8) *61.4 (29.3–91.5) 
Adiponectin 
( g/ml) 
7.9 (7.6–10.3) 7.8 (5.4–16.9) 8.6 (4.2–11.3) 
 
Table 5.2 Characteristics of the cohort living in Qatar 
Data are expressed as mean ± standard deviation or as median (interquartile 
range). BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood 
pressure, HOMA-IR: homeostatic model assessment – insulin resistance, HDL: 
high-density lipoprotein, LDL: low-density lipoprotein, chol: cholesterol. 
*denotes p < 0.05 comparing the obese group to all other groups. 
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5.3.2 Glucose, insulin, proinsulin and GLP-1 parameters 
in a cohort living in Qatar 
The fasting and postprandial glucose levels in the three groups were comparable 
and were within normal range (Figure 5.2 A, B and C). 
Fasting insulin was significantly higher in obese subjects (median (interquartile 
range) was 15.5 (5.8–19.8) mIU/L) compared to normal-weight and overweight 
subjects (p < 0.05). The postprandial insulin response to the meal at 30 minutes 
increased significantly (p < 0.05) compared to baseline, and this elevation 
remained even at 120 minutes in all three groups. There were no significant 
differences in postprandial response at 30 and 120 minutes between the three 
groups (Figure 5.3 A, B and C). 
The fasting proinsulin levels in the three groups were comparable (normal-
weight, overweight and obese groups’ median (interquartile range) were 8.15 
(5.75–12.37), 8.4 (5.97–12.22) and 10.7 (6.1–14.5) pmol/L, respectively). 
Postprandial proinsulin levels had increased significantly (p < 0.05) at 30 minutes 
in all groups, and remained elevated even at 120 minutes (Figure 5.4 A, B and C). 
Fasting GLP-1 levels were comparable in all three groups; the median 
(interquartile range) of the normal-weight group was 2.0 (1.9–2.0) pmol/L; for 
the overweight group it was 1.8 (1.7–2.2) pmol/L, and for the obese group was 
2.1 (1.9–2.4) pmol/L. Postprandial GLP-1 levels had increased significantly (p < 
0.05) at 30 and 120 minutes compared to baseline in all three groups. However, 
there were no significant differences in postprandial GLP-1 response to the meal 
between either normal-weight and obese groups or normal-weight and 
overweight groups (p > 0.05) (Figure 5.5 A, B and C). 
  
 155 
Variables Normal weight Overweight Obese 
 
Fasting glucose 
(mmol/L) 
 
4.5 (± 0.4) 
 
4.7 (± 0.3) 
 
4.5 (± 0.1) 
 
30 m PP glucose 
(mmol/L) 
 
4.7 (± 0.48) 
 
5.1 (± 0.7) 
 
5.2 (± 0.8) 
 
120 m PP glucose 
(mmol/L) 
 
4.1 (± 0.37) 
 
4.6 (± 0.5) 
 
4.5 (± 0.7) 
 
Fasting insulin 
(mIU/L) 
 
4.8 (3.5–5.3) 
 
5.2 (4.2–6.2) 
 
15.5 (5.8–19.9) 
 
30 m PP insulin 
(mIU/L) 
 
49.1 (30.5–54.2) 
 
50.0 (32.4–57.0) 
 
74.7 (38.6–111.6) 
 
120 PP insulin 
(mIU/L) 
 
28.0 (21.2–35.8) 
 
33.4 (25.6–50.3) 
 
53.5 (23.6–65.8) 
 
Fasting proinsulin 
(PM) 
 
8.2 (5.7–12.4) 
 
8.4 (6.0–12.2) 
 
10.3 (6.1–14.5) 
 
30 m PP proinsulin 
(PM) 
 
36.5 (14.8–43.4) 
 
23.7 (19.5–29.3) 
 
26.8 (13.1–51.9) 
 
120 m PP proinsulin 
(PM) 
 
33.7 (27.4–59.3) 
 
43.6 (21.4–66.1) 
 
41.1 (22.1–66.3) 
 
Fasting GLP-1 
(PM) 
 
2.0 (1.9–2.9) 
 
1.8 (1.7–2.2) 
 
2.1 (1.9–2.4) 
 
30 m PP GLP-1 
(PM) 
 
8.9 (3.7–11.2) 
 
7.2 (4.7–8.6) 
 
10.7 (6.0–30.1) 
 
120 m PP GLP-1 
(PM) 
 
7.5 (6.6–10.1) 
 
4.9 (2.7–8.3) 
 
7.0 (2.9–12.1) 
 
Table 5.3 Fasting and postprandial (30 and 120 minutes) levels of glucose, 
insulin, proinsulin and GLP-1 in the normal-weight, overweight and obese groups 
from Qatar 
Data were expressed as mean ± standard deviation or as median (interquartile range). 
m = minute, PP = postprandial.  
 156 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Fasting and postprandial glucose levels in normal-weight (A), 
overweight (B) and obese (C) groups 
Normal fasting and postprandial glucose levels were compared in the three 
groups, and no significant differences were apparent in the basal and postprandial 
glucose levels among the three groups (A, B and C). Data are expressed as median 
and interquartile range. Min = minute. 
  
 157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Fasting and postprandial insulin levels in normal-weight (A), 
overweight (B) and obese (C) groups 
The obese group had significantly elevated basal insulin levels compared to 
normal and overweight groups (p = 0.005) (A, B and C). The postprandial insulin 
response increased significantly at 30 minutes (p < 0.05) in the three groups, and 
this increase remained significant at 120 minutes in all groups (A, B and C). Data 
are expressed as median and interquartile range. Min = minute. 
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Figure 5.4 Fasting and postprandial proinsulin levels in normal-weight (A), 
overweight (B) and obese (C) groups 
Fasting and postprandial proinsulin was comparable between the three groups (p 
> 0.05). Postprandial proinsulin increased significantly at 30 minutes and 
remained elevated at 120 minutes. Data are expressed as median and 
interquartile range. Min = minute. 
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Figure 5.5 Fasting and postprandial GLP-1 levels in normal-weight (A), 
overweight (B) and obese (C) groups 
There were no significant differences in basal and postprandial GLP-1 levels 
between the three groups (p > 0.05). Data are expressed as median and 
interquartile range. Min = minute. 
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5.3.3 Adipokine level in the cohort living in Qatar 
Figure 5.6 A shows the leptin levels in the three different weight groups of the 
cohort living in Qatar. Leptin concentrations were significantly higher in the obese 
group compared to normal-weight and overweight groups (p = 0.01). However, 
adiponectin levels were comparable for the three groups (Figure 5.6 B). 
  
 161 
 
 
 
Figure 5.6 Adipokine levels in normal-weight, overweight and obese 
groups 
Leptin level (A) was significantly greater in obese groups compared to normal-
weight and overweight groups (p = 0.01). However, there were no significant 
differences in adiponectin level between the three groups (B). Data are expressed 
as median and interquartile range. NW: normal weight, OW: overweight, OB: 
obese. 
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5.4 Discussion 
The prevalence of obesity in the Middle Eastern region was the highest worldwide 
in 2013 [335]. In Qatar, the obesity rate among females was 32% in 2010 [336]. 
Whether there is any lesion in the gut–brain axis that would affect the satiety 
mechanism and lead to hyperphagia in that particular group of individuals had 
not been investigated previously in this region. In this study, GLP-1 hormone, a 
mediator that is involved in the satiety process, was investigated in normal-
weight, overweight and obese female subjects living in Qatar. 
However, no differences in either basal or postprandial GLP-1 secretion were 
found between the three groups. Therefore, impairment in postprandial GLP-1 
secretion was not found in these obese subjects, and the phenomenon of weight 
gain seems not to be related to a disorder in triggering satiety by postprandial 
GLP-1 secretion in response to caloric intake. This of course does not rule out the 
involvement of other gut peptides such as GIP. 
In contrast with this result, it was reported that attenuated postprandial GLP-1 
secretion in response to oral carbohydrate but not fat intake is found in obese 
individuals compared to lean individuals living in England [140]. The conflict in 
the two results might be explained by the differences in BMI of obese subjects; 
BMI was lower in the current study (32.5 ± 1.6 kg/m2) compared to that of 
Ranganath et al. (40.1 ± 8 kg/m2). Moreover, in the current study, a mixed meal 
consisting of 40 g of carbohydrate, 17.4 g of fat and 18 g of protein was used as a 
meal challenge test, whereas Ranganath’s group used a carbohydrate- (100 g) and 
fat-rich (37.8 g) meal for the challenge. 
As no physiological defect in satiety index or in the mediator postulated, GLP-1, 
could be found in the current study, the susceptibility to obesity and diabetes in 
the Middle East region could be explained by a sedentary lifestyle, lack of activity 
and high caloric intake. Supporting this suggestion is the difference that was 
found in the 2-hour insulin response between the two groups of subjects living in 
Qatar and those living in London. The two groups had a comparable fasting insulin 
level. However, the postprandial insulin concentrations were significantly 
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elevated 30 minutes after the ingestion of a meal, and importantly these levels 
remained elevated even 120 minutes after meal in the group of people living in 
Qatar compared to the group living in London, despite their younger age and 
comparable BMI. Moreover, leptin levels were also higher in the group of people 
living in Qatar compared with those living in England, despite having comparable 
BMI; this result supports greater fat mass in the Qatar dwellers, perhaps as a 
result of the sedentary lifestyle in Qatar, which might explain the high prevalence 
of obesity and diabetes in this region. 
Postprandial hyperinsulinaemia is accompanied by elevated systemic proinsulin, 
which may further facilitate prolonged hyperinsulinaemia and might be an 
indicator of ER stress. A study conducted in San Francisco on normal-weight, 
healthy South Asian and Caucasian subjects to investigate insulin response after 
a 75 g OGTT found that while fasting insulin was similar in both groups, the 
postprandial insulin response was greater in South Asians. The 2-hour insulin 
level was especially greater in Asian women compared to the Caucasians, and it 
was concluded that South Asians have a defect in insulin-stimulated glucose 
uptake [337]. A further study was carried out to find out whether the increase in 
insulin response is accompanied by elevated GLP-1 secretion. A comparison 
between eight healthy young South Asian and ten Caucasian men with reference 
to fasting and postprandial glucose, insulin and GLP-1 levels in response to OGTT 
showed comparable fasting glucose, insulin and GLP and postprandial glucose 
levels between the two groups. However, the postprandial insulin and GLP-1 
responses as well as the AUC for insulin and GLP-1 were greater in South Asians. 
It was concluded that increased postprandial GLP-1 might be a possible 
explanation for the higher insulin levels in South Asians [338]. Although the South 
Asians had similar results as regards the high insulin response to the group of 
subjects living in Doha in the current study, postprandial GLP-1 levels in this 
group did not seem to be related to elevated 2-hour postprandial insulin levels. 
Two-hour postprandial hyperinsulinemia was also reported in a normal glucose 
tolerance Nauruan population, and it was concluded that this elevation in 
postprandial insulin level strongly predicts development of impaired glucose 
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tolerance and diabetes [339]. Thus, elevated postprandial levels of insulin-like 
molecules may be an early, sensitive marker for the metabolic defect that 
precedes diabetes disease in the Middle Eastern population. 
Like Qatar, Nauru has also had rapid increases in the rate of obesity and diabetes 
that accompanied a dramatic and rapid change in the economic status of the 
island. Due to the discovery of large deposits of phosphate, the income of 
Nauruans increased, and it became, for a short period of time, one of the countries 
with the highest per capita incomes in the world. This led to a transition from a 
traditional to a western diet along with a sedentary lifestyle and high caloric 
intake, which were correlated with the high incidence of obesity and diabetes in 
this region [340]. In a similar way, inactivity and sedentary lifestyle could be a 
contributing factor to high rates of obesity and diabetes in the Middle East. 
Therefore, early detection of abnormal postprandial insulin response and 
prevention of progress to metabolic disorder with lifestyle interventions such as 
LCD, and more importantly exercise and active lifestyle, may yield encouraging 
health benefits. 
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Chapter 6 
 
Discussion 
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This thesis examined the role that GLP-1 might play in three separate scenarios: 
firstly, in the chronic N&V symptoms experienced by some patients following 
bariatric surgery; secondly, in patients undergoing a new surgical weight-loss 
technique; and thirdly, in an obesity-prone population. All three of the studies 
were novel; obesity is likely to be at least partly mediated by changes in GLP-1 
secretion and function and therefore examination of GLP-1 is warranted. 
Chronic persistent N&V after RYGB surgery has been found to be associated with 
an elevation in basal GLP-1 level, and it was concluded that elevated basal GLP-1 
might partly contribute to chronic undesirable N&V symptoms experienced by 
some patients after RYGB surgery. Increased GLP-1 concentrations may therefore 
also explain similar symptoms seen after other bariatric procedures that result in 
alteration of gut hormone secretion, such as SG [310] but not GB, as increased 
GLP-1 secretion is not reported after this surgical technique [247]. 
In this study, the kit that was used to measure GLP-1 did not detect all forms of 
active GLP-1. It detected only GLP-1 (7-36); therefore, it would be useful if a 
similar study could be conducted in the future measuring all active forms of GLP-
1 (7-36) and (7-37), as both forms have been found to affect satiety [341, 342]. 
These patients with elevated GLP-1 might benefit from being treated with a 
specific GLP-1 antagonist such as exendin (9-39). In the current study, 
intervention with a generalized GLP-1 antagonist (somatostatin) was tried, but 
only in one patient; it led to amelioration of N&V symptoms along with a reduction 
in GLP-1. A larger cohort to confirm both the chronic elevation in fasting GLP-1 
and amelioration of N&V symptoms along with a reduction in systemic GLP-1 
after treatment with a specific GLP-1 antagonist is required before this can be 
recommended as an effective management for those patients. However, these 
preliminary results offer an encouraging, possibly effective, avenue for future 
exploration in a group of patients who are considered particularly difficult to 
manage clinically. 
This is also the first study to show a direct effect of GLP-1 on adipose leptin 
secretion. Inhibition of leptin secretion in vitro was found after 16 hours but not 
4 hours of exposure to GLP-1. After the RYGB procedure, chronic exposure to GLP-
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1 might contribute to a reduction in leptin levels. Therefore, the finding that 
patients with persistent N&V had a lower leptin level compared to patients 
without N&V after the RYGB procedure could be due to a chronic elevation in 
fasting GLP-1 levels in this group. How this might alter leptin sensitivity, both 
centrally and peripherally, requires further investigation. It has been reported in 
rats that chronic administration of liraglutide significantly reduces fasting 
circulating leptin levels and body fat percentage more than that seen with caloric 
restriction [343]. Thus, it will be beneficial to find out in the future whether 
chronic administration of GLP-1 agonist to obese individuals with 
hyperleptinaemia could reduce leptin levels and enhance leptin sensitivity, and 
whether GLP-1 agonists such as exendin-4 and liraglutide could be used as 
therapeutic medications for weight loss besides their use in type 2 diabetes. 
POSE is a novel, minimally invasive and incisionless endoscopic technique for 
weight loss. Our study revealed that POSE provides a reasonable short-term 
weight-loss outcome in the morbidly obese; however, it is not as effective as RYGB 
in the longer term. Moreover, as compared to RYGB, its impact on improved 
glycaemic homeostasis and insulin secretion, and increased postprandial GLP-1 
hormone was all minimal. It might be useful to consider the POSE procedure in 
obese individuals with a lower BMI (30–35). As it was found that weight loss was 
reported in the first 2 months following POSE, it might also be useful to consider 
this technique as a more effective alternative method to LCD for weight reduction 
preceding bariatric surgery. However, further studies are required in larger 
sample cohorts and for longer periods post-surgery to carefully compare this new 
procedure to RYGB, as well as other procedures such as gastric band and sleeve. 
Lastly, GLP-1 secretion was examined in a population susceptible to obesity and 
type 2 diabetes. No attenuation in the secretion of GLP-1 was found in obese 
individuals that could explain a decrease in satiety and increased caloric intake. 
An interesting finding was the increased 2-hour insulin response in the young 
normal-weight women living in Doha with no apparent metabolic disease, 
compared to those living in London, although the fasting insulin and glucose levels 
were normal in both groups. That finding could be explained by little physical 
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activity and a sedentary lifestyle. This finding might also be an early indicator for 
future development of diabetes, so it would be useful to follow up those 
individuals identified with postprandial hyperinsulinaemia for a long period of 
time to monitor development of diabetes. In addition, based on this result, the 
research group at ADLQ has already started another project that aims to find out 
the effect of exercise on late postprandial hyperinsulinaemia among individuals 
living in Doha, and whether a change in lifestyle could ameliorate the postprandial 
insulin resistance and could be considered as a preventative intervention for 
development of diabetes. 
Finally, all the studies were carried out in female individuals; whether the results 
would be any different among males also needs to be explored. 
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Appendices 
 
 
 
 
Medication 
 
 
Group 1 
N&V 
 
 
Citalopram, vitamin B12 injection, iron tablet, fluoxeline, 
lansoprazole, clozapine 
Group 2 
No N&V 
 
Vitamin B12 injection, ramipril, amlopidine, iron tablet, 
citalopram, vitamin D and calcium 
Group 3 
MO 
 
Acetazolamide, fluoxeline, lansoprazole, Adalat 
Group 4 
OW 
 
Atenolol, amlopidine 
Group 5 
NW 
 
No medication 
 
Appendix 1: Medication of patients in the N&V study. 
The five groups of patients (1–5; Chapter 3) differed in terms of treatment as 
specified in the table. N&V: nausea and vomiting, MO: morbidly obese, OW: obese 
and overweight, NW: normal weight. 
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Medication 
 
 
POSE 
 
 
Metformin 1 g, gliclazide 30 mg 
 
RYGB 
 
Metformin 3 g, metformin 1 g, pioglitazone 50 mg 
 
 
Appendix 2: Medication of patients in the POSE vs RYGB study. 
The two groups of patients (POSE and RYGB; Chapter 4) differed in terms of 
treatment as specified in the table. POSE = primary obesity surgery endoluminal, 
RYGB= Roux-en-Y gastric bypass. 
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Medication 
 
 
Group 1 
NW 
 
 
No medication 
Group 2 
OW 
 
No medication 
Group 3 
OB 
 
No medication 
 
Appendix 3: Medication of subjects in an obesity-prone Arab population 
study. 
The three groups of subjects (1–3; Chapter 4) were not on any medication, as 
specified in the table. NW: normal weight, OW: overweight, OB: obese. 
